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Abstract
Galectins are a family of -galactoside-binding proteins involved in cell stress responses and
differentiation. Galectins are multifunctional proteins widely studied in many cell models
including acute myeloid leukemia HL-60 cells where they mediate numerous intra- and
extracellular functions in response to many stress-inducing stimuli. O-GlcNAcylation is a
dynamic post-translational modification implicated in the regulation of many cellular
diseases including cancers. The O-GlcNAc mediated expression and secretion of galectins
during neutrophilic differentiation was examined in HL-60 cells. Galectin gene (LGALS),
galectin protein expression, and galectin secretion were determined by RT-qPCR,
immunoblotting, and ELISA, respectively. Inhibition of O-GlcNAcylation induced markers
of differentiation namely growth arrest, segmented nuclear morphology, and H2O2
production by NADPH oxidase comparable to ATRA-induced differentiation. The reduction
of O-GlcNAcylation modified galectin expression, and increased galectin secretion in a
manner similar to ATRA. This study confirms that inhibition of O-GlcNAcylation is one of
the important mechanisms regulating expression and secretion of galectins and cellular
differentiation.
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Summary for Lay Audience
Galectins are a family of -galactoside-binding proteins widely studied in many cell models
including HL-60 acute myeloid leukemia cells where they mediate many intra- and
extracellular functions in response to many stress inducing stimuli. Acute myeloid leukemia
(AML) is cancer occurring in immune cells of the myeloid lineage. Cancer is characterized as
uncontrollable cell growth and division that results in the formation of tumors which
negatively affect the normal cells and tissues nearby. Uncontrolled growth is often caused by
gene mutations that can both upregulate genes that force cells through signaling pathways
that promote growth and downregulate genes that keep cell division in check and suppress
tumor formation. In AML, the cancer occurs in cells with more stem-like features that
promote high growth and proliferation. These cells ordinarily will continue to develop and
differentiate throughout their life cycle until they terminally differentiate into a cell type that
can no longer divide. AML can be treated clinically using therapies that induce this terminal
differentiation thus limiting tumor expansion. However, some differentiation therapies are
not universally applicable therefore in this study, we sought to investigate the potential of OGlcNAcylation modulation as a method of terminal differentiation. Many cancers display
aberrant O-GlcNAcylation, a post-translational modification that regulates protein function,
with many more proteins modified by this sugar in cancer cells than in healthy cells. In this
study, I used ATRA to induce granulocytic differentiation of HL-60 cells and compares the
results to those obtained by treatment biochemical inhibitors of enzymes that regulate OGlcNAcylation to disrupt O-GlcNAc homeostasis. Reduction of protein O-GlcNAcylation
led to slowed growth of AML cells, increased expression of galectins, and phagocytic
activity similar to what is seen when cells are treated with established differentiation
chemicals. Neutrophils induced by either ATRA, or inhibition of O-GlcNAc showed high
expression levels of neutrophil-specific genetic markers, segmented nuclear morphology, and
increased reactive oxygen species production compared to promyeloid cells, confirming that
targeting O-GlcNAcylation can induce terminal differentiation. This provides novel insight
into AML regulatory mechanisms and could be used to develop more utilitarian
chemotherapies.
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Chapter 1

1

Introduction

1.1 Galectins
Galectins are a family of multifunctional, soluble, glycan-binding proteins found in
animal cells characterized by carbohydrate recognition domains that preferentially
recognize -galactosides (Robinson et al., 2019). First discovered in 1975 as a family of
S-type lectins, galectins differ from other lectins in their recognition of  -galactosides
(Robinson et al., 2019). Galectins were first distinguished by the name galectin in 1994
(Barondes et al., 1994) and are distinguished from previously discovered carbohydrate
binding proteins by the lack of calcium-dependence in the glycan binding that is observed
in C-type lectins. Galectins are found in many cellular compartments, in the extracellular
matrix, and in circulation. The secretion of galectins is poorly understood, and the
mechanisms are not well documented in the literature. Galectins lack an N-terminal
sequence necessary for secretion through the canonical secretion pathway, and as such
galectins must be secreted through non-canonical mechanisms (Popa et al., 2018).
Galectins can be biomarkers of differentiation status of cells. Some galectins increase in
expression in more differentiated cells whereas others are more highly expressed in lessdifferentiated cells (Abedin et al., 2003; Vinnai et al., 2017).
The galectin proteins fall into three main categories based on their structural properties:
prototype, tandem-type, and chimeric galectins (Figure 1) (Timoshenko, 2015). Prototype
galectins contain only one carbohydrate-recognition-domain (CRD) and can exist as
monomers or in some cases as homodimers as reported by Robinson and co-workers
(Robinson et al., 2019). Prototype galectins include galectins – 1, -2, 5, -7, -10, -11, -13, 14, -16. Tandem type galectins contain two CRDs which are joined by a non-CRD linker
region and are larger than prototype galectins. Tandem-type galectins may homo- or
heterodimerize (Robinson et al., 2019). Tandem-type galectins include galectins -4, -8, 9, and -12. The only known chimera type galectin is galectin-3. Galectin-3 has the ability
to pentamerize via the N- terminal domain. Galectin-3 is a widely studied 26 kDa protein
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Figure 1. The molecular structure of galectins.
Galectins are classified based on the carbohydrate recognition domain (yellow and
green), non-lectin linker domain (blue) and N-terminal end domain (orange). Prototype
galectins contain one CRD and can form homodimers. Tandem-repeat galectins contain
two non-identical CRDs connected by a non-lectin linkage peptide region. Chimera-type
galectin-3 is monomeric and may pentamerize via the N-terminal end domain (orange
circle). The figure is adapted from (Timoshenko, 2015).
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which functions ranging from participation in antimicrobial activity of leukocytes, to
mitotic cleavages with galectin-3 being a binding partner of the nuclear mitotic apparatus
protein (Magescas et al., 2017).

1.1.1 The roles of galectins expressed in HL-60 cells
Previously, the expression of six galectins was confirmed in HL-60 cells by RT-qPCR
(Vinnai et al., 2017) including galectins -1, -3, -8, -9, -10, and -12. Thus, there are two
prototype galectins -1, and -10, three tandem type galectins -8, -9, and -12, and the
chimera type galectin-3. The HL-60 cell line originated from the blood of a 36-year-old
Caucasian female with acute myeloid leukemia and has been used to study many cellular
pathways in the context of cell differentiation. Previous reports indicate that some
galectins are inducible by differentiation stimuli (Abedin et al., 2003; Vinnai et al., 2017).
It has also been reported that galectins play many roles in neutrophil function in vivo
(Robinson et al., 2019) thus making HL-60 cells a suitable functional model to study
differential regulation of galectins.

1.1.1.1

Galectin-1 (LGALS1)

Galectin-1 is a prototype galectin expressed in HL-60 cells whose role in neutrophilic
differentiation and relation to the fate of the cell is reported in different ways. Expression
of this protein in the undifferentiated promyeloid cell has been documented by many
(Abedin et al., 2003; Vinnai et al., 2017), yet the expression profile among the
differentiated neutrophil like cell has been differentially reported (Vinnai et al., 2017;
Vakrushev et al., 2018). While neutrophilic differentiation can be induced by at least two
chemicals, dimethyl sulfoxide (DMSO) (Breitman et al., 1980b) and all-trans-retinoicacid (ATRA) (Breitman et al., 1980a), previous work shows that galectin-1 is upregulated
in HL-60 cells induced to differentiate with DMSO (Vinnai et al., 2017), yet is
downregulated when induced by ATRA (Vakrushev et al., 2018). Chiarotti et al. (1994)
also report differential induction of the LGALS1 gene where they observed upregulation
by thyroid stimulating hormone and downregulation by retinoic acid. Galectin-1
participates in differentiation of different types of cells, as it reported to be important in
the skeletal muscle differentiation in human mesenchymal stem cells (Chan et al., 2006)
and in granulocytic differentiation. In mature neutrophils, galectin-1 promotes human
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neutrophil migration by inducing actin cytoskeleton rearrangements during noninflammatory conditions (Auvynet et al., 2012). Galectin-1 is multi-functional and has
widely reported roles, some of which appear contradictory. Galectin-1 is reported to be a
pro-survival molecule in AML, by activating Ras GTPase and stimulating
phosphatidylinositol-3-kinase and protein kinase B activity, and downstream mitogen
activated protein kinase signaling which progresses the cell through the cell cycle and
proliferation (Elad-Sfadia et al., 2002; Ruvolo et al., 2020).
Galectin-1 promotes immunosuppression and tumor progression by remodeling the tumor
endothelium to suppress T-cell infiltration thus inhibiting T-cell mediated immune
clearance (Nambiar et al., 2019). This is achieved by galectin-1-mediated T-cell
apoptosis (Perillo et al., 1995; Kovács-Sólyom et al., 2010). Galectin-1 like other
galectins has opposing roles reported in the literature as it has also been reported that
galectin-1 expression correlates with tumor aggressiveness in other cancer types (Saussez
et al., 2008).

1.1.1.2

Galectin-3 (LGALS3)

Galectin-3 is a 26 kDa lectin protein. Mature leukocytes express galectin-3 and secrete it
to the circulation where it can interact with immunoglobin E and the immunoglobin E
receptor, signaling an oxidative burst through the nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase complex to produce reactive oxygen species (ROS) which
are used as microbicides by neutrophils (Robinson et al., 2019), and this signaling can be
inhibited using neutralizing antibodies. Galectin-3 is important in some types of cells for
proper mitotic cleavage and cytokinesis of daughter cells after DNA replication. In
previous studies, galectin-3 associated with the nuclear mitotic apparatus protein to
regulate proper spindle pole formation and allowed both mitosis and cytokinesis to occur
properly (Magescas et al., 2017). When galectin-3 was inhibited or knocked out, the
nuclear mitotic apparatus protein did not function as expected and as such, spindle pole
formation occurred improperly and at inappropriate cytosolic locations. This led to
bizarre cleave patterns and atypical distribution of chromosomes among daughter cells.
The interaction of galectin-3 with the nuclear mitotic apparatus protein is O-GlcNAc
dependent (Magescas et al., 2017).
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Galectin-3 signaling through CD66a and CD66b may result in ROS production and IL-8
secretion (Robinson et al., 2019). Galectin-3 deficient neutrophils have an impaired
laminin binding to the endothelium, a necessary process in neutrophil mediated immunity
(Gittens et al., 2017). Inhibition of galectin-3 results in reduced TNF KC, TGF, and
MCP-1 levels and neutrophil accumulation, suggesting a role for galectin-3 in
extravasation and chemotaxis (Pan et al., 2018). Extravasated neutrophils may bind to
laminin and fibronectin in galectin-3-mediated mechanisms suggesting a role for
galectin-3 in chemotaxis (Zhou et al., 1993; Ozeki et al., 1995; Kuwabara and Liu, 1996;
Kerszetes et al., 1997). Galectin-3 also facilitates neutrophil phagocytosis of
Streptococcus pneumoniae (Farnworth et al., 2008). Not only bacteria can be cleared in
this way, as there were fungal infections such as Candida parapsilosis, and Candida
albicans can be phagocytosed by neutrophils through galectin-3 mediated mechanisms
(Linden et al., 2013; Kohatsu et al., 2016).

1.1.1.3

Galectins-8, -9, -10, and -12 (LGALS8, LGALS9, LGALS10,
LGALS12)

Galectin-8 is a tandem repeat galectin implicated in many cell functions including
adhesion, proliferation, and apoptosis (Robinson et al., 2019). Galectin-8 has opposing
roles, as it has been reported to induce apoptosis in thymocytes (Tribulatti et al., 2007),
whilst in brain cells it is reported to prevent apoptosis (Metz et al., 2016). Galectin-8 has
been reported in the ROS production aspect of neutrophils by signaling through the Cterminal domain (Nishi et al., 2003; Nishi et al., 2006). Galectin-8 can regulate neutrophil
adhesion to the endothelium (Yamamoto et al., 2008).
Galectin-9 is also a tandem-repeat galectin and is widely studied for its association with
T-cell immunoglobin domain and mucin domain 3 (Tim-3). Tim-3 mediates galectin-9
enhancement of neutrophil microbial killing (Robinson et al., 2019). Galectin-9 also
causes neutrophil degranulation and ROS production in a Tim-3 dependent manner
(Vega-Carrascal et al., 2014; Steichen et al., 2015). Galectin-9 can also regulate
neutrophil chemotaxis (Hirao et al., 2015). Galectin-9 was previously known by the name
eotaxin, as it was discovered in eosinophils where researchers noted that galectin-9
exhibited chemotactic activity (Matsumoto et al., 1998; Hirashima, 1999). Galectin-9 was
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also shown to enhance phagocytosis of P. aeruginosa (Farnworth et al., 2008; Stowell et
al., 2010; Arthur et al., 2015). Tim-3 appears to be a necessary partner in galectin-9
mediated phagocytosis. Galectin-9 and the interaction with Tim-3 is well documented.
The binding of these two proteins is implicated in many pathways associated with cell
growth and proliferation (Zheng et al., 2019). Galectin-9 and Tim-3 interaction activate
phosphatidylinositol-3-kinase and mTOR resulting in increased expression of hypoxia
inducible factor 1 and the secretion of vascular endothelial growth factor (Gonçalves
Silva et al., 2015 Prokhorov et al., 2015). These proteins play a role in angiogenesis
(Zhang D et al., 2018) and are reported as important for the progression of leukemias
(Lin et al., 2018). There is additional evidence for galectin-9 in the promotion of cell
growth. The galectin-9-Tim-3 interaction may also activate extracellular signal regulated
kinase and protein kinase B resulting in -catenin signaling and activation of nuclear
factor B (Kikushige et al., 2015). Nuclear factor B activation promotes the expression
and secretion of cytokines and chemokines and growth factors stimulating the growth and
proliferation of leukemias (Jia et al., 2016; Gao B et al., 2018). Galectin-9 also induces Tcell death through its interaction with Tim-3 (Cao et al., 2018). The T-cell apoptosis
mediated by galectin-9 is consistent with reported functions of galectin-1 in remodeling
the tumor microenvironment conferring immunosuppression to the tumor
microenvironment and promoting tumor progression (Saussez et al., 2008; KovácsSólyom et al., 2010; Nambiar et al., 2019). Galectin-1 and -9 can thusly be seen as
oncogenic markers and as such implicates them as target molecules for potential future
cancer therapies.
Genetic expression of LGALS10 can be induced after neutrophilic differentiation of HL60 cells (Abedin et al., 2003). Largely studied in eosinophil models, galectin-10 is also
known as the Charcot-Leyden crystal protein. It was initially thought to belong to the
lysophospholipase family due to weak lysophospholipase activity (Swaminathan et al.,
1999) even though there was little to no structural or sequence homology to other
proteins of this family. However, it was reclassified in 1997 as a member of the galectin
superfamily when it was discovered to have sequence homology to other galectins
(Leffler et al., 2002). Charcot-Leyden crystal proteins oligomerize in the extracellular

8

matrix to form crystals visible by brightfield microscopy (Dvorak et al., 1998). These
crystals have a role in allergy mediation and responses.
Galectin-12 according to the literature can play opposite roles in cellular differentiation.
While some (Yang et al., 2004) report that galectin-12 expression promotes adipocyte
differentiation, others (Xue et al., 2016) report that knockdowns of galectin-12 enhance
ATRA-induced neutrophilic differentiation of the human NB4 promyelocytic leukemia
cells. However, this does not mean that galectin-12 inhibits differentiation, as this same
group (Xue et al., 2016) reports that absent a knockdown, there is still a high degree of
differentiation as assessed by ROS production using a NADPH-oxidase functional assay.

1.1.2 The secretion of galectins
Galectins as previously mentioned are multifunctional proteins that have roles in both the
intracellular and extracellular environments (Robinson et al., 2019). Extracellularly,
galectins have been reported to regulate differentiation of various cell types (Hikita et al.,
2000; Hirashima et al., 2004; Chan et al., 2006). Secretion of proteins through the
conventional vesicular secretion pathway is well documented and understood. Proteins
possessing an N-terminal signal sequence or hydrophobic segment are directed to the
endoplasmic reticulum and anchored into its membrane by the N-terminal sequence.
Proteins then pass through the endoplasmic reticulum to the Golgi apparatus and finally
trafficked to the plasma membrane in membrane bound vesicles (Popa et al., 2018).
However, not all proteins are conventionally secreted, and galectins are included in this
group of proteins that use non-conventional secretion mechanisms (Popa et al., 2018).
Galectin-1 may use the same route as FGF2 for its secretion, the most studied nonconventionally secreted protein that uses direct translocation (Popa et al., 2018). Both
galectin-1 and -3 may accumulate under the plasma membrane prior to secretion (Cooper
and Barondes, 1990; Mehul and Hughes, 1997) which may suggest a direct translocation
mechanism for their secretion. Cooper and Barondes (1990) also showed that galectin-1
may be secreted by extracellular vesicle formation. Galectin-1 accumulates under the cell
surface, where micro-vesicles form and load the galectin-1, which then bleb out and
release galectin-1 into the extracellular matrix. Galectin-3 can be secreted by clathrin-
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independent carriers (Lakshminarayan et al., 2014). The mechanisms for secretion of
galectin-1 are not confirmed but the literature does suggest a few different mechanisms
for secretion absent an N-terminal sequence. One study (Seelenmeyer et al., 2005)
hypothesized the secretion of galectin-1 was accomplished by counter receptors.
Secretion of galectin-3 may require the removal of O-GlcNAc beforehand (Mathew et al.,
2021). Galectin-3 can be secreted from cells when glycosylated proteins are unavailable
(Popa et al., 2018) however, others have reported that cells grown in a serum-free
medium showed secrete less galectin-3 than cells grown in a serum-containing medium
(Sato et al., 1993). Currently, while it is known that galectins can be secreted from cells
and act on extracellular surface proteins (Barondes et al., 1994), the mechanisms for the
secretion of galectins remain to be elucidated (Popa et al., 2018).

1.2 Acute myeloid leukemia
Acute myeloid leukemia (AML) is cancer occurring in the myeloid lineage and are
subdivided into eight subtypes under the French-American-British classification. The
different AML subtypes occur in different cell types within the myeloid linage, at varying
stages of maturation and differentiation (Figure 2). As such, an AML patient will have
their cancer classified as one of the eight French-American-British subtypes (M0-M7)
based on morphological and genetic characteristics of the cancer (Dalton et al., 1988).
Acute promyeloid leukemia (APL) is designated as an M3 AML under the FrenchAmerican-British classification system. APL is a rare form of AML comprising
approximately 5% of all leukemia. M3 leukemias are famously known for their
susceptibility to all-trans-retinoic acid (ATRA). ATRA has long been used in the clinical
setting as a chemotherapeutic for M3 AML with great success. Previous literature
reported a remission rate over 90% for M3 AML patients administered ATRA.
Unfortunately, some other forms of AML exhibit ATRA-resistance and as such are
unable to be clinically treated in this manner (Johnson and Redner, 2015). Early research
into this phenomenon reported that 98% of APL patients have the t(15:17) translocation
which resulted in a fusion of the retinoic acid receptor alpha (RAR) with the
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Figure 2. The French American British classification system of acute myeloid
leukemia.
The above figure shows the designation of AML subtypes among various cells within
myeloid linage (adapted from Szalontay and Shad, 2014). Myeloid leukemia is classified
into eight different subtypes numbered M0-M7 based on the cell type carrying the
leukemia within the myeloid linage. Leukemias are classed on maturity of the cell type
within the myeloid lineage. This is determined by light microscopy to determine
morphology and by the expression of genetic biomarkers.
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promyelocytic leukemia gene (PML) called the PML-RAR (Gallagher, 2002; Tomita et
al., 2013). ATRA-induced differentiation does not need to signal through the PMLRAR fusion protein however, as some non-M3 leukemias including the AML cell line
HL-60, classified as M2 (Dalton et al., 1988), are also susceptible to ATRA-induced
differentiation through RAR or retinoid X receptor signaling (Breitman et al., 1980a;
Tassef et al., 2017). ATRA works as a differentiation agent by interacting with the RAR
and downstream signaling leads to the activation of transcription factors C/EBP and
PU.1 which activate the transcription of genes involved in neutrophilic differentiation of
promyeloid cells (Bjerregaard et al., 2003; Akagi et al., 2010; Ai and Udalova, 2019).
Past studies have shown that in vivo deficiencies of C/EBP family transcription factors
specifically the  and  proteins resulted in defective myeloid differentiation and mice
lacking these proteins were highly susceptible to fatal infections (Akagi et al., 2010).
The RAR family has three proteins, , , and , which are all structurally similar yet
differ in the tissue type in which they are expressed. RAR is highly expressed in
epithelial tissues whereas  is highly expressed in hematopoietic tissues (Johnson and
Redner, 2015). The RAR is usually always DNA bound and the target genes remain
inactive due to the additional binding of a co-repressor complex (Nagy et al., 1999).
Binding of the ligand (ATRA) induces a conformational change and dissociation of the
co-repressor complex leading to activation and transcription of the target genes (Nagy et
al., 1999; Ablain and de The, 2011). Retinoic acid is also used as a differentiation agent
in other cell models including SY5Y human neuroblastoma cells (Ammer and Schulz,
1994).

1.2.1 The HL-60 cell line as a model of neutrophilic differentiation
HL-60 cells are an M2 AML isolated from a 36-year-old female patient in 1976 and in
the following year the immortalized cell culture which came to be known as the HL-60
line was established at the National Cancer institute (Collins et al., 1977). This cell line
was later discovered to be susceptible to ATRA-induced terminal differentiation
confirming the original clinical diagnosis of M3 APL (Breitman et al., 1980a). Although
originally thought to belong to the M3 subtype because the patient had a high proportion
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of progranulocytes, HL-60 cells were reclassified as M2 in 1988 due to the morphology
of these cells better fitting the M2 classification (Dalton et al., 1988). Although HL-60
cells were reclassified as an M2 leukemia due to the morphological features, the HL-60
cell line is susceptible retinoic acid signaling and resulting in granulocytic differentiation
(Breitman et al., 1980a). As such, HL-60 remains a suitable model for studying
neutrophilic differentiation and ATRA signaling in APL. These cells can be cultured in a
serum free growth medium as was first discovered in the 1980s by Breitman et al.
(1980b). Commercial fetal bovine serum (FBS) contains many growth factors, proteins,
and hormones that are used to enhance the growth of cell cultures in vitro. The Breitman
group determined the minimal essential supplements needed to add to a culture media to
allow HL-60 cells to grow, these being insulin, transferrin, and selenous acid (ITS)
(Breitman et al., 1980b). Insulin is necessary to allow glucose uptake and metabolism and
transferrin allows iron uptake which cells need to use as a cofactor for protein activity in
many cellular processes. Selenous acid is a compound of the element selenium, a cofactor
for enzymes in redox pathways such as peroxiredoxin. The absolute necessity of
selenium compounds is however debatable as the Breitman group, even in their serumfree pioneering paper show that absent a selenium supplement, HL-60 cells were still
culturable in RPMI. They noted previous literature which suggested the necessity of
selenium (Guilbert and Iscove, 1976; McKeehan et al., 1976) yet did not show that
growth and culture was impossible absent selenium. The Breitman group however kept
selenium in their supplement and even today this remains a common supplement for cell
culture, as there are several commercially available ITS cocktails. The insulin and
transferrin requirements are absolute, as absent these growth factors, cell growth ceases
immediately (Breitman et al.,1980a; Collins, 1987).
A serum-free method of culture is important for this work which seeks to learn about the
secretion of galectins from HL-60 cells. As galectins are soluble proteins and previously
secretion has been reported, they are found in serum as was confirmed by several groups
independently (Barrow et al., 2011; He et al., 2017; Asiamah et al., 2019). The presence
of galectins in serum will contribute to background signal in ELISA assays or other
assays. To remove the background and measure the extracellular galectins, ensuring that
only galectins which were secreted by the HL-60 cells of interest, we will employ the
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serum-free culture method pioneered by Breitman et al. (1980b). Serum-free cell culture
has also been used to assess galectin secretion by murine B cells (Yu et al., 2006). Since
there are many components of serum aside from the minimal necessary for culture (ITS)
and the effect of these with regards to growth, proliferation, signaling, differentiation,
oncogenesis and more may not be fully understood, this study will use both a serumcontaining and serum-free method of culture to compare the measurements and assess the
role that serum may play.
HL-60 cells have a homozygous deletion of the p53 gene (Soddu et al., 1994). P53
induces G1 growth arrest in cells and the absence of this gene product in part contributes
to the infinite proliferative capacity of this cell line (Ray et al., 2010). P53 is known as
the guardian of the genome (Lane, 1992) that activates the expression of genes that
control cell cycle progression and apoptosis (Levrero et al., 2000 Yang A et al., 2004).
P53 degradation by Mdm2 signals cells to undergo apoptosis (Ray et al., 2010).
However, HL-60 cells transfected with p53 show increases in apoptosis and
differentiation (Soddu et al., 1994) showing that normal cell cycle regulation can be
rescued by targeting those pathways dysregulated in cancers.
There are several inducers of neutrophilic differentiation of HL-60 cells (Stegmaier., et al
2004; Peck et al., 2006). Collins (1987) published a review paper detailing the different
inducible lineages of HL-60 cells and reporting the markers for each type of
differentiation. Specifically, for granulocytic differentiation many markers of
differentiation are listed. These include upregulation of surface receptors confirmed using
flow cytometry-based assays, such as CD11b and CD15, down-regulation of surface
markers like the insulin receptor (IR) and transferrin receptor , increased expression of
components of the NADPH oxidase complex such as neutrophil cytosolic factor 1
(NCF1) and neutrophil cytosolic factor 2 (NCF2), increased capacity for reduction of
nitro blue tetrazolium dye, and increased ROS production by directly measuring
hydrogen peroxide evolution using an activator of the NADPH oxidase complex. While
there are many markers of granulocytic differentiation, HL-60 cells need not meet all the
criteria in order to be classified as differentiated. Indeed, previous experiments by Sham
et al, (1995) and Manda-Handzlik et al, (2018) sought to elucidate how HL-60 cells
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induced to the granulocyte lineage by different drugs differentially express and regulate
key components of the neutrophil.
HL-60 cells are an adequate model to study granulocytic differentiation and to study
proteins and post-translational modifications in the context of differentiation. A
promyelocyte which is pre-leukocytic can differentiate into all types of mature leukocytes
and indeed there is much literature on the induction of differentiation of HL-60 cells to
many cell types. Terminal differentiation can be induced by phorbol 12-myristate 13acetate (PMA) which will yield monocyte cells or by sodium-butyrate which will yield
eosinophil cells. Most interestingly, HL-60 cells can be induced to the granulocyte
lineage with the use of several chemicals (Abedin et al., 2003). DMSO is a long used and
widely used differentiation agent for HL-60 cells (Abedin et al., 2003). ATRA is another
drug which has long been used in research settings to induce HL-60 cells to the
granulocyte lineage (Breitman et al., 1980a). What’s more is that ATRA has also been
used to some success in the clinical treatment of acute myeloid leukemia. While DMSO
and ATRA may both induce neutrophilic differentiation and this can be confirmed by the
expression of neutrophil specific genes like NCF1, and also by the NADPH-oxidase
complex production of hydrogen peroxide, the entirety of induction and suppression
between these two drugs varies quite a lot. Some biomarkers do not have the same
magnitude of change between DMSO and ATRA, such as the reduction of global OGlcNAcylation. Sherazi et al, (2018) used DMSO and reported a 95% drop in OGlcNAcylated proteins, whereas Asthana et al. (2018) used ATRA and show a less
severe reduction, although this group did not quantify this reduction in their report. The
method of action of both of these drugs is not the same and as such there should be some
expected differences in the cellular response.
Galectins have previously been studied in relation to DMSO-induced granulocytic
differentiation of HL-60 cells (Vinnai et al., 2017). Although galectin regulation during
granulocytic differentiation has only been studied by few, more classical markers of
differentiation have been studied in response to multiple known inducers of granulocyte
differentiation (Manda-Handzlik et al., 2018). Retinoic acid induced galectin gene
transcription utilizes specificity protein 1 consensus binding sites (Lu and Lotan, 1999;
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Lu et al., 2000). Many galectins have this promoter, and this appears to be a common
feature of gene regulation in this gene family (Chiarotti et al., 1999; Dyer and Rosenberg,
2001). The previous association of galectin upregulation and DMSO-induced neutrophilic
differentiation (Vinnai et al., 2017) combined with the many reported roles of galectins in
neutrophils reviewed by Robinson et al. (2019) and the differential regulation of
neutrophilic markers reported by Manda-Handzlik et al. (2018) bring into question the
utility of galectins as biomarkers using either DMSO or ATRA as an inducing agent.
Leukemia can be treated by the induction of terminal differentiation. Cancer cells
upregulate Yamanaka factors which are oncogenes, and display a more stem cell-like
morphology, genetic profile, and functional activity, lending to the nigh-infinite
proliferative capacity. Induction of terminal differentiation forces stem-cell-like cancer
cells through their respective developmental stages to a cell type which lacks expression
of oncogenes and does not have the capacity to proliferate indefinitely (Breitman et al.,
1981). Regarding acute myeloid leukemias, differentiated cells have lower expression
levels of genes that signal cells through the proliferative pathways, specifically the IR,
and the transferrin receptor. Chaplinski et al. (1986) showed that HL-60 cells fated to the
granulocyte linage by DMSO or ATRA express significantly less IR than untreated HL60 cells. The transferrin receptor also known as CD71 is similarly downregulated upon
DMSO induced differentiation (Mollinedo et al., 1998; Santos-Beneit and Mollinedo,
2000). The downregulation and subsequent ablation of signaling through these receptors
is not immediate however, as the expression decreases further and further over time
(Mollinedo et al., 1998). Differentiation by DMSO or ATRA is achieved 3-7 days post
stimulation with the differentiation agent (Mollinedo et al., 1998).
Neutrophils are leukocytes involved in the process of innate immunity. Neutrophils are
highly abundant in circulation (Ai and Udalova, 2019), and are one of the earliest and
most effective responders to microbial infection (Kobayashi et al., 2005). Neutrophils can
use less specific response mechanisms to recognize and remove infection without
antibody mediated opsonization of pathogens (Barton, 2006). Neutrophils can also
interact with antibodies to focus effector function on more specifically targeted
pathogenic invaders as well (Barton, 2006), as is evidenced by the increased expression
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of immunoglobin E receptors and Fc receptors on the cell surface of mature neutrophils
(Collins, 1987). Neutrophils are dedicated phagocytes that mediate innate immune
function through many microbicidal activities (Belambri et al., 2018). One important and
highly functional method of dealing with invading pathogens is by the production of ROS
through the NADPH oxidase complex (Belambri et al., 2018). This complex is formed by
several protein subunits which are upregulated in more maturated leukocytes relative to
the promyeloid precursor cell (Vinnai et al., 2017; Dakik et al., 2021). Additionally,
upregulation of subunit proteins of the NADPH oxidase complex during granulopoiesis is
associated with upregulation of galectins-3 and -8 (Drewniak et al., 2008). The complex
however is not constitutively active and does not produce ROS until it is assembled and
activated through a series of phosphorylation steps by protein kinase C (PKC) (Bedard
and Krause, 2007). Neutrophils can be activated by a variety of stimuli including
recognition of pathogen associated molecular patterns through the abundant pathogen
recognition receptors on the cell surface (Robinson et al., 2019). Signaling through
pathogen recognition receptors leads to downstream activation of PKC which
phosphorylate the many subunits of the NADPH oxidase complex, inducing the
association of the subunits and initiating functional microbicidal activity. There are also
agonists for this pathway as the ROS production can be stimulated by formyl-methionylleucyl-phenylalanine which is a bacterial cell wall component which is recognized by the
formyl peptide receptor or can be activated by direct activation of the PKC enzyme using
chemicals like PMA (Dakik et al., 2021). The NADPH oxidase complex oxidizes
NADPH and transfers that electron to diatomic oxygen to create a superoxide ion and
ultimately hydrogen peroxide as a result (Figure 3) (Bedard and Krause, 2007; Belambri
et al., 2018). Hydrogen peroxide and other ROS exert phagocytic activity by inducing
oxidative damage on the pathogens within phagolysosomes (Bedard and Krause, 2007).
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Figure 3. ROS production via the NADPH oxidase complex requires neutrophil
activation and PKC activity.
The above figure details the activation and relocation of the NADPH oxidase complex
subunits (adapted from Belambri et al., 2018). The protein subunits of the NADPH
oxidase complex are expressed in dedicated phagocytes. The NADPH oxidase activity is
only exerted upon activation of the cell which can be achieved by formyl-methionylleucyl-phenylalanine (fMLP) signaling to activate PKC or directly activating PKC using
PMA. PKC activation phosphorylates the subunits and induced the association of the
subunits which oxidize NADPH to convert oxygen into superoxide. Superoxide is rapidly
converted into hydrogen peroxide by superoxide dismutase.
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1.3 O-GlcNAcylation
O-GlcNAcylation is a cellular post-translational modification where an O-linked, -Nacetyl-D-glucosamine (O-GlcNAc) is added to the hydroxyl groups of serine and
threonine residues of proteins (Figure 4). The precursor molecule, uridine diphosphate Nacetylglucosamine (UDP-GlcNAc), is produced by the hexosamine biosynthesis pathway
(HBP) which catalyzes intermediates from the glycolysis pathway into UDP-GlcNAc
which participates in many cellular processes (Akella et al., 2019). The rate-limiting step
of the HBP is the conversion of fructose-6-phosphate to glucosamine-6-phosphate, a
reaction which is catalyzed by the enzyme glutamine fructose-6-phosphate
aminotransferase (GFAT) (Martinez et al., 2017). UDP-GlcNAc is also used to produce
proteoglycans, glycolipids, and glycoproteins (Grønning-Wang et al., 2013). OGlcNAcylation occurs on serine and threonine residues and thus, competes with
phosphorylation. The large size of the GlcNAc moiety provides steric hinderance to the
residue, prevent other post-translational modifications from occurring on that site and on
adjacent sites (Liu and Li, 2018). O-GlcNAc inhibitors used in cell culture also showed
that for hundreds of proteins, when O-GlcNAcylation is inhibited that the
phosphorylation of many proteins was enhanced (Wang et al., 2008) and vice versa, when
O-GlcNAc is elevated, the phosphorylation of many proteins was decreased. OGlcNAcylation appears to be controlled by only two enzymes: O-GlcNAc transferase
(OGT) and O-GlcNAcase (OGA). OGT catalyzes the addition of the sugar moiety by
cleaving the UDP region and linking the GlcNAc to the hydroxyl group of serine or
threonine residues, hence the nomenclature “O-linked.” The reverse reaction is catalyzed
by the enzyme OGA (Asthana et al., 2018). The two enzymes involved are very
important biologically and evolutionarily playing important roles in cellular functions. As
such, significant disturbances to this homeostasis are stressful to the cells, with some
reporting that OGT knockouts were fatal in mice (Zhang et al., 2015).
O-GlcNAc is implicated in cytokinesis of cells (Li et al., 2017). These authors reported
that OGT knockdown by siRNA led to decreased phosphorylation at Ser-71 which
hampered vimentin filament severing and led to failure of cytokinesis. This agrees with
other literature which reports decreases in cell growth and mitosis when treated with
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Figure 4. The hexosamine biosynthesis pathway in mammalian cells.
The above figure shows the synthesis of UDP-GlcNAc through the HBP and the
enzymatic regulation of O-GlcNAcylation (adapted from Fardini et al., 2013). The rate
limiting step of the HBP is the conversion of fructose-6-phosphate to glucosamine-6phosphate via the GFAT enzyme. The product of the HBP is UDP-GlcNAc which is
added to serine or threonine residues of proteins with the OGT enzyme, removing the
UDP in the process to allow the N-acetylglucosamine to bind through the oxygen
molecule of the residues. The removal of O-GlcNAc is catalyzed by the OGA enzyme.
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inhibitors of OGT and GFAT (Perez-Cervera et al., 2013; Asthana et al., 2018). Vimentin
phosphorylation is enhanced when OGT or OGA are overexpressed, suggesting an
interaction with O-GlcNAc bearing polymers which promote the phosphorylation at Ser71 (Komura et al., 2012; Liu and Li, 2018).
OGT plays an important role in insulin signaling (Perez-Cervera et al., 2013). The IR is
glycosylated by the OGT enzyme and allows signaling through the IR which is a receptor
tyrosine kinase and initiates many downstream activities. There appears to be a positive
feedback loop regulating the interaction between the IR and OGT. OGT is relocated to
the plasma membrane by phosphatidylinositol triphosphate which must first be
phosphorylated by the phosphatidylinositol-3-kinase enzyme which is only active when
signaled by the IR. The relocation of the OGT to the plasma membrane allows the OGlcNAcylation of the IR, and continued flux through this pathway. Literature (PerezCervera et al., 2013) shows that inhibition of either the IR or OGT, has a negative effect
on the other. When O-GlcNAcylation can be inhibited by chemical inhibitors or by RNA
interference techniques, signaling through the IR is ablated, limiting the downstream
actions of the IR signaling pathway. This lends credence to the O-GlcNAc being
important for the infinite proliferatively of cancerous cells. OGT can itself be OGlcNAcylated (Perez-Cervera et al., 2013; Martinez et al., 2017), showing a positive
feedback loop and demonstrating that O-GlcNAc is very important even for its own sake.
OGT is linked to Yamanaka factors, maintaining pluripotency and self-renewal (Jang et
al., 2017). Specifically, Sox2 and Oct4 are O-GlcNAcylated, and this is associated with
the embryonic stem cell state (Jang et al., 2017). As embryonic stem cells differentiate
into embryoid bodies, the O-GlcNAcylation on these oncogenes decreases rapidly (Jang
et al., 2017). Blocking the O-GlcNAcylation of proteins in these cells inhibited selfrenewal whereas increasing the O-GlcNAcylation maintained embryonic stem cell
pluripotency (Jang et al., 2017)
O-GlcNAc homeostasis is an important regulator of cancer biology. Many different types
of cancers in a variety of cell types in humans display aberrant O-GlcNAcylation
associated with the cancerous phenotype of the cell (Sherazi et al., 2018; Akella et al.,
2020). This is displayed in vitro, and in vivo as previous researchers showed that healthy
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peripheral blood mononuclear cells have less O-GlcNAcylated proteins than peripheral
blood mononuclear cells isolated from leukemia patients (Asthana et al., 2018). In vitro,
cancer cells that are terminally differentiated show reduced O-GlcNAcylation compared
to the cancerous cells. This also works in vivo as mice peritoneally injected with APL
tumors and treated with inhibitors of GFAT or OGT to reduce the O-GlcNAcylation
showed a cessation in the growth of the tumors (Asthana et al., 2018).
Many pathways have been implicated in O-GlcNAc mediated signaling. For example, the
pentose phosphate pathway (PPP) (Rao et al., 2015) requires O-GlcNAcylation for the
proper functioning of intermediates in the pathway. The PPP produces biomolecules
necessary for proliferation and mitosis (Patra and Hay, 2014). The end products of the
pathway are only made when glucose-6-phosphate dehydrogenase (G6PD) is OGlcNAcylated and activated, thus catalyzing the reactions and allowing flux through the
PPP. When G6PD is not O-GlcNAcylated, cells do not grow, proliferate, or divide as
much. This shows how runaway proliferation which is a defining characteristic of cancer
cells can be mitigated by targeting O-GlcNAc and O-GlcNAc mediated pathways.
Increased O-GlcNAcylation is shown to be protective and is associated with many
cellular stress states (Martinez et al., 2017). Some models suppose that while elevated OGlcNAc acutely is protective, chronic elevation is toxic. This is not unique to OGlcNAcylation as acute heat shock protein upregulation plays a role in protecting cells
from heat-shock, yet chronic heat shock protein upregulation is toxic in cells (Roth et al.,
2014). O-GlcNAc reduces ER stress, regulates the heat shock response, disrupts protein
aggregation in neurodegenerative diseases, mediates the inflammatory driven stress
response, and enables cancer cells to resist stressful tumor microenvironments (Zachara
et al., 2004; Akimoto et al., 2007; Pathak et al., 2012; Yi et al., 2012; Yuzwa et al., 2014;
Jang et al., 2015; Rao et al., 2015).
O-GlcNAcylation is also implicated in cell differentiation. Stem cells frequently have
higher protein O-GlcNAcylation than cells in more differentiated states in numerous cell
types (Shi et al., 2010; Andres et al., 2017; Sherazi et al., 2018). How O-GlcNAcylation,
or the lack thereof signals cells through the differentiation process is not entirely
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understood. It is known that cancer cells, including leukemias, display aberrant OGlcNAcylation and that genetic manipulations and drugs that target the O-GlcNAc cycle
are effective in the induction of terminal differentiation, however the exact mechanism of
this regulation is not fully characterized in HL-60 cells. It is known that reduction in OGlcNAcylation can limit cell proliferation (Rao et al., 2013) which could prove useful to
limit uncontrolled cell division characteristic of many cancers. Currently, how
neutrophilic differentiation of HL-60 cells and the transcription of genes associated with
this process is related to reduction of global O-GlcNAcylation remains to be fully
elucidated.
O-GlcNAcylation detection has evolved over time. Many methods of O-GlcNAcylated
protein detection are available and used by researchers today. Ma and Hart, (2017) detail
a mass spectrometric approach to the detection of modified proteins. Collision induced
dissociation allows for confirmation of O-GlcNAcylation but does not allow for site
mapping due to breakage of the glycosidic bond holding the sugar moiety to the peptide
due to the high energy in the ionization process by the electro-spray ionizer whereas a
fragmentation method known as electron transfer dissonance can be used for site
mapping. Non-mass spectrometry methods of detecting O-GlcNAcylated proteins have
been developed in recent years. There are at least two commercial antibodies available.
The RL2 antibody available from ThermoFisher Scientific and the CTD110.6 available
from Santa Cruz Biotechnologies. The RL2 antibody can be used in both western blot
and immunodot blot to detect modified proteins (Asthana et al., 2018; Sherazi et al.,
2018).
O-GlcNAcylation of galectins is not well understood. Only two of the sixteen galectins
are known to be O-GlcNAcylated, although bioinformatic analysis using the YinOYang
1.2 server suggested that all galectins have at least one predicted site of O-GlcNAcylation
(Tazhitdinova and Timoshenko, 2020). Galectin-1 was confirmed to be a target of this
post translational modification in previous literature (Hart et al., 2011). Only recently has
there been evidence of O-GlcNAcylation on another galectin, which has been reported in
a 2021 pre-print confirming O-GlcNAcylation of galectin-3 (Mathew et al., 2021).
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O-GlcNAcylation is associated with cancerous cells (Shi et al., 2010) and is reduced in
HL-60 cells that have undergone granulocytic differentiation (Asthana et al., 2018,
Sherazi et al., 2018). Differentiation of HL-60 cells also changes the expression of
various galectins in response to the differentiation stimulus (Abedin et al., 2003; Vinnai
et al., 2017). O-GlcNAcylation is thought to inhibit the secretion of proteins including
galectins. Secretion is hypothesized to first necessitate de-glycosylation of the GlcNAc
moiety. In this study, we will investigate the relationship between the expression and
secretion of galectins, neutrophilic differentiation, and O-GlcNAcylation.

1.4 Hypothesis
Most studies on galectins in cell biology focus on only a single galectin with galectin-3
being very commonly studied. Previously, the Timoshenko lab has characterized the
regulation of galectins in response to oxidate stress and DMSO-induced granulocytic
differentiation in HL-60 cells (Vinnai et al., 2017) as well as a global inhibition of OGlcNAcylation in differentiated cells (Sherazi et al., 2018). Others have also investigated
the differentiation in response to disruption of O-GlcNAc homeostasis (Asthana et al.,
2018). To date, no other published studies have attempted to combine galectin regulation
in neutrophilic differentiation with O-GlcNAc mediated regulation of galectins. A new
concept has been introduced recently that O-GlcNAcylation may regulate trafficking and
secretion of galectins (Tazhitdinova and Timoshenko, 2020) (Figure 5). My study was
designed within the framework of this concept to examine the effects of O-GlcNAc
modulation on the expression and secretion of galectins in the context of neutrophilic
differentiation.
I will test the hypothesis that by inhibiting O-GlcNAcylation, HL-60 cells will
undergo terminal differentiation and secrete galectins in a manner similar to the
effects of a known differentiation stimulus. The rationale behind this study is that
reduction in O-GlcNAcylation is important in the differentiation process and that by
targeting enzymes that regulate O-GlcNAc homeostasis, we can induce terminal
differentiation in the absence of a traditional differentiation stimulus such as ATRA.
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Figure 5. O-GlcNAc sensitive neutrophilic differentiation of HL-60 cells.
The above figure illustrates the hypothesis of this study, detailing the proposed
mechanism of O-GlcNAc mediated HL-60 differentiation (adapted from Tazhitdinova
and Timoshenko, 2020). ATRA is a known inducer of neutrophilic differentiation and is
associated with a decrease in global O-GlcNAcylation of intracellular proteins. OGlcNAc cycle enzyme inhibition is proposed to induce differentiation and regulate
galectin expression bypassing the ATRA-RAR interaction.
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Objective 1: To characterize and compare ATRA-induced neutrophilic differentiation of
HL-60 cells in serum-containing and serum-free media as a platform for modeling
galectin-free conditions in cell culture.
Objective 2: To study the expression profile and distribution of galectins between
intracellular and extracellular compartments and compare this distribution between
progenitor and differentiated HL-60 cells.
Objective 3: To study the effects of O-GlcNAc cycle enzyme inhibitors on the expression
profiles and distribution of galectins between intracellular and extracellular
compartments of HL-60 cells.

30

Chapter 2

2

Materials and Methods

2.1 Chemicals and solutions
All-trans-retinoic-acid (ATRA) (R2625), 6-diazo-5-oxo-L-norleucine (DON) (D2141),
horseradish peroxidase (P-8250), thiamet G (TG) (SML0244), DMSO (D26500),
Dulbecco′s Phosphate Buffered Saline (DPBS) with MgCl2 and CaCl2 (D8862),
Immobilon Classico Western HRP substrate (WBLUC500), and scopoletin (S2500) were
purchased from Sigma-Aldrich Canada (Oakville, ON). DPBS without calcium and
magnesium (311-425-CL), 100x ITS Universal Culture Supplements (315-081-QL), and
Iscove’s Modification of Dulbecco’s Modified Eagle Medium (IMDM) (319-105-CL)
were purchased from Wisent Bio Products (Saint-Jean-Baptiste, QC EDTA (EB0185),
Mammalian Protease Inhibitor Cocktail (BS386), 2x RIPA Buffer IIII with EDTA and
EGTA (pH 7.4) (RB4477), sodium azide (NaN3) (S2002), bovine serum albumin (BSA)
(AD0023), and sodium orthovanadate (Na3VO4) (SB0869) were purchased from
BioBasic (Markham, ON). SsoAdvanced Universal SYBR® Green Supermix (1725274),
and non-fat dry milk blotting-grade blocker (1706404) were purchased from Bio-Rad
(Mississauga, ON). VECTASHIELD Vibrance Mounting Medium with DAPI (H-1800)
was purchased from Vector Laboratories (Burlingame, CA). Phorbol 12-myristate 13acetate (PMA) (PMA168) was purchased from BioShop (Toronto, ON). TRIzol®
(15596018) was purchased from Life Technologies (Toronto, ON). Fetal Bovine Serum
(FBS) (12484-028), and SYBR™ Safe DNA Gel Stain (S33102) were purchased from
ThermoFisher (Mississauga, ON). Acryl/Bis™ 29:1 ULTRA PURE 40% (w/v) Solution
(0311) was purchased from VWR Life Science (Mississauga, ON). Froggarose LE
Molecular Biology Grade Agarose (A87) was purchased from FroggaBio (Concord, ON).
OGT inhibitor 2-acetamido-1,3,4,6-tetra-O-acetyl-2-deoxy-5-thio-a-D-glucopyranose
(Ac-5SGlcNAc) was synthesized in Dr. Vocadlo laboratory (Gloster et al., 2011) and
kindly provided as per Material Transfer Agreement between Simon Fraser University
and the University of Western Ontario.
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2.2 Cell culture and treatments
Human acute promyelocytic leukemia cell line HL-60 (ATCC® CCL-240TM) was
obtained from ATCC. Cells were cultured as a suspension in IMDM without antibiotics
and supplemented with either 10% FBS (IMDM-FBS) or ITS (5 g/mL human insulin, 5
g/mL human transferrin, 5 ng/L selenous acid) (IMDM-ITS) in a humidified incubator
at 37oC, 5% CO2. Cells were sub-cultured two to three times weekly in 100 mm
suspension culture dishes (83.3902.500) from Sarstedt and concentration was kept below
106 cells/mL. Cell viability was determined using the trypan blue (0.4%) exclusion test
and was not less than 90% except where indicated. Population doubling time (PDT) of
cell cultures was calculated using the following equation:

PDT = (T2-T1) / (3.322log10(N2/N1))
where, N1 an N2 are cell concentrations at T1 and T2 time points within the exponential
phase of cell growth.
To induce granulocytic differentiation, HL-60 cells were grown in either 60 mm or 100
mm suspension culture dishes from Sarstedt and treated with 1 M ATRA for 72 hours as
described elsewhere (Zhang et al., 2018). To change global O-GlcNAcylation, the cells
were treated with 10 M TG (OGA inhibitor) (Sherazi et al., 2018), 25 M AC (OGT
inhibitor) (Sherazi et al., 2018), or 12.5 M DON (GFAT inhibitor) (Asthana et al., 2018)
for up to 72 hours using either a single dose or daily supplementation every 24 hours.

2.3 RNA isolation, cDNA synthesis, and PCR gene
expression assays
Following treatments, cells were centrifuged for 5 min at 300 × g, washed once with icecold DPBS without Mg2+ and Ca2+, and the total mRNA was isolated from cell pellets
using TRIzol® reagent according to manufacturer’s protocol. The mRNA samples were
dissolved in sterile nuclease-free water and their purity and quantity were assessed with
the Thermo ScientificTM Nanodrop 2000c UV-Vis spectrophotometer considering an
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A260/280 ratio of > 1.8 as a minimum threshold for use in later assays. cDNA was
synthesized from 500 ng of mRNA using the High-Capacity cDNA reverse transcription
Kit from Applied Biosystems (4368813) as per the manufacturer’s protocol.
All primers for polymerase chain reaction (PCR) assays were synthesized by BioCorp
UWO OligoFactory (Western University, Department of Biochemistry, Ontario) and
verified by BLAST (Table 1). The T100 Thermo Cycler (Bio-Rad) was used to perform
end-point PCR amplification in 20 L reaction volumes as described elsewhere (Vinnai
et al., 2017). Reaction mixtures consisted of 2X Taq FroggaMix from FroggaBio
(FBTAQM), 1 M forward primer, 1 M reverse primer and 0.5 L of undiluted cDNA.
PCR amplicons were separated on a 2% agarose gel prepared in TAE buffer (20 mM
Tris, 40 mM Acetic Acid, 1.2 mM EDTA) containing SYBR® Safe and imaged using a
Molecular Imager GelDoc XRT (BioRad) with Image Lab software, version 6.0 (BioRad). The SsoAdvanced Universal SYBR® Green kit (cat. 1725274) from Bio-Rad was
used for real-time quantitative PCR (qPCR) amplification of samples (20 L) containing
1 M forward primer, 1 M reverse primer, and 0.5 L of undiluted cDNA.
Quantification of mRNA transcripts was performed in a CFX ConnectTM Real-Time PCR
Detection System (Bio-Rad) using 2-step cycling regime following polymerase activation
for 2 min at 95oC: 40 cycles of denaturation (5 s, 95oC) and annealing (25 s, 60-65oC).
Temperatures varied based on primer pair and are listed in Table 1. Specificity of qPCR
amplification was verified by the presence of a single melt peak at a specific temperature
for each amplicon. Relative transcript levels were calculated by the Livak method (2-ΔΔ
CT

) using −actin (ACTB) as a reference gene (Schmittgen and Livak, 2008).

2.4 Protein isolation and immunoblotting
Following treatments, cells were centrifuged at 300 × g for 5 min and the supernatants (810 mL) were collected and frozen at -80oC to use later for analyses of extracellular
proteins. The cell pellets were washed twice with ice-cold PBS and lysed in 300 L of
RIPA buffer (50 mM Tris-HCl, pH 7.4, 0.1% sodium dodecyl sulfate, 0.5% w/v sodium
deoxycholate, 5 mM EDTA, 1 mM EGTA and 150 mM NaCl) supplemented with 100
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Table 1. PCR primer sequences and characteristics
Size
Gene name

2 step
cycling

PMID
reference

220

95°C (5 s)
60°C (25 s)

23108139

108

95°C (5 s)
60°C (25 s)

18202194

172

95°C (5 s)
62°C (25 s)

30504378

91

95°C (5 s)
62°C (25 s)

18202194

82

95°C (5 s)
62°C (25 s)

30504378

111

95°C (5 s)
65°C (25 s)

18202194

93

95°C (5 s)
60°C (25 s)

23147401

767

95°C (5 s)
60°C (25 s)

10754283

95

95°C (5 s)
62°C (25 s)

Designed

95

95°C (5 s)
60°C (25 s)

30504378

Sequence 5'-3'
bp

LGALS1

LGALS3

LGALS8

LGALS9

LGALS10
(CLC)

LGALS12

NCF1

NCF2

MYC

F

CCTGGAGAGTGCCTTCGAGTG

R

CTGCAACACTTCCAGGCTGG

F

CAGAATTGCTTTAGATTTCCAA

R

TTATCCAGCTTTGTATTGCAA

F

TGGGGACGGGAAGAGATCAC

R

TGCCATAAATGCCCAGAGTGTC

F

CTTTCATCACCACCATTCTG

R

ATGTGGAACCTCTGAGCACTG

F

GGATGGCCAAGAATTTGAACTG

R

GGTGTAAGAGGATTGGCCATTG

F

TGTGAGCCTGAGGGACCA

R

GCTGAGATCAGTTTCTTCTGC

F

GTCAGATGAAAGCAAAGCGA

R

CATAGTTGGGCTCAGGGTCT

F

CGAGGGAACCAGCTGATAGA

R

CATGGGAACACTGAGCTTCA

F

CCTGGTGCTCCATGAGGAGAC

R

CAGACTCTGACCTTTTGCCAGC

F

TCAGCAAGCAGGAGTATGACGAG

ACTB
R

ACATTGTGAACTTTGGGGGATG
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M phenylmethylsulfonyl fluoride, 100 M Na3VO4, 1 M bestatin, 1.4 M E-64, 1 M
leupeptin, 0.08 M aprotinin and 1.5 M pepstatin A. The cell lysates were incubated on
ice for 10 min and centrifuged at 12,000 × g for 15 min at 4oC. Total protein
concentration was quantified using the DCTM Protein Assay Kit II (5000112) from BioRad and BSA as a standard by measuring absorbance at 655 nm in a model 3550
Microplate Reader (Bio-Rad).
To analyze global levels of selected galectins and O-GlcNAc, the protein samples were
immobilized onto nitrocellulose membrane (0.22 m pore size, GE Healthcare 1060006)
using a Bio-Dot® Microfiltration apparatus (Bio-Rad) as previously described (Sherazi et
al., 2018). Briefly, the nitrocellulose membrane was prewetted in Tris-buffered saline
(TBS: 20 mM Tris-HCl, pH 7.5, 150 mM NaCl) and placed into the apparatus. Each well
was loaded with 200 l of whole cell protein extract (20 g/mL in DPBS) and proteins
were transferred to the membrane by gravity filtration for 90 min. Afterwards, the
membrane was blocked with a 3% non-fat dry milk reconstituted in TBST buffer (TBS
plus 0.05% Tween 20) for 60 min at room temperature, washed three times with TBST
and incubated overnight at 4oC with an appropriate primary antibody solution (15 mL) in
TBST supplemented with 5% BSA and 0.05% sodium azide. The membrane was washed
again three times with TBST and then incubated with either goat-anti-mouse or goat-antirabbit IgG-HRP conjugated secondary antibody diluted 1:10,000 in a 5% non-fat dry
milk reconstituted in TBST for 1 hour at room temperature with light agitation. Lastly,
the TBST-rinsed membrane with immunodots was evenly covered with 1.5 mL of
Immobilon Classico chemiluminescent reagent (Sigma-Aldrich, WBLUC0500) and
imaged using a ChemiDoc XRS system with Quantity One Software, version 4.6.6. For
western blot analysis, samples of cell lysates were mixed with a loading buffer (2% (w/v)
SDS, 0.04% BME), boiled for 5 min, loaded on 4% polyacrylamide stacking gel (25 g
protein per lane), and electrophoretically separated by SDS-PAGE in 12%
polyacrylamide resolving gel (100 V, until blue tracker dye reaches the bottom of the
gel). The proteins were transferred from the gel to 0.22 m PVDF membrane (SigmaAldrich, 03010040001) at a constant voltage of 20 V at 4oC overnight using wet transfer
in a 25 mM Tris, 190 mM glycine, 20% (v/v) methanol (pH 8.3) buffer. Blocking,
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antibody incubation, and imaging steps for western blots were performed as described
above for immunodot blots. The primary and secondary antibodies were obtained from
Santa Cruz Biotechnology (Dallas, Texas), Abcam Canada (Toronto, Ontario), and
ThermoFisher Scientific (Mississauga, ON) (Table 2).

2.5 Scopoletin assay to measure PMA-induced H2O2
production
H2O2 production by HL-60 cells was measured by scopoletin/peroxidase fluorescence
assay using an AMINCO-Bowman Series 2 luminescence spectrometer as described
earlier (Vinnai et al., 2017) with minor modifications. Briefly, cell culture suspension
was centrifuged for 5 min at 300 × g, and cells were washed twice with and resuspended
in DPBS containing Mg2+ and Ca2+ to yield a concentration of 6x105 cells/mL. Scopoletin
(500 nM) and HRP (20 g/mL) were added to 2 mL of the cell suspension, which was
prewarmed for 5 min in a cuvette of the fluorimeter at 37oC before adding 1 M of PMA.
A decrease in fluorescence of scopoletin was monitored at 460 nm (excitation at 350 nm)
and the maximal slope of the recorded traces was calculated in RStudio (version 4.0.5) to
quantify the rate of H2O2 generation by cells (Vinnai et al., 2017).

2.6 Fluorescence microscopy and nuclear staining
To prepare slides for nuclear staining, HL-60 cells were diluted to a concentration of
5x105 cells/mL in 200 L and were centrifuged onto glass slides for 5 min at 500 rpm
using the Shandon Cytospin 2 centrifuge (Vinnai, 2016). The attached cells were fixed
with chilled methanol for 5 min and staining of nuclei was achieved by mounting the
slides with DAPI-contained VECTASHIELD Vibrance Mounting Medium. An
AxioImager A1 fluorescent microscope (Carl Zeiss) equipped with DAPI filter cube was
used to view the slides. The images were taken with a high-resolution monochrome
XCD-X700 CCD camera (Sony Corporation) using Northern Eclipse 8.0 software from
Empix Imaging (Mississauga, Ontario).
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Table 2. Primary and secondary antibodies used for immunodot blot and western blot
assays.
Antigen

Host

Type

Conjugates

Dilution

Source

Catalog #

Galectin-1

Mouse

monoclonal

N/A

1:800

Santa-Cruz

sc-166618

Galectin-3

Rabbit

polyclonal

N/A

1:200

Santa-Cruz

sc-20157

Galectin-9

Rabbit

monoclonal

N/A

1:1,000

Abcam

ab227046

Galectin-10

Rabbit

monoclonal

N/A

1:10,000

Abcam

ab157475

O-GlcNAc (RL2)

Mouse

monoclonal

N/A

1:1,000

ThermoFisher

MA1-072

Mouse IgG (H+L)

Goat

polyclonal

HRP

1:10,000

ThermoFisher

A16066

Rabbit IgG (H+L)

Goat

polyclonal

HRP

1:10,000

ThermoFisher

A16096
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2.7 Enzyme-linked immunosorbent assay (ELISA)
Extracellular concentrations of human galectin-1, galectin-3, and galectin-9 were
measured using SimpleStep ELISA® kits from Abcam as described by the manufacturer.
For all three kits, cell culture supernatant samples were diluted 4-fold in the supplied
sample diluent that was found to fall within the range of concentrations that correspond to
the standard curve. Absorbance at 450 nm was measured using a Model 3550 Microplate
Reader (Bio-Rad).

2.8 Statistical analysis
One-way ANOVA followed by Tukey’s multiple comparisons test, two-way ANOVA
followed by Tukey’s multiple comparison test, Student’s t-test and Pearson’s correlation
test were performed using GraphPad Prism, version 6.01 for Windows (GraphPad
Software, La Jolla California USA, www.graphpad.com). All experiments were
conducted using a minimum of three biological replicates. Data were presented as means
± SD and differences between means were considered significant at p < 0.05.
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Chapter 3

3

Results

3.1 Comparison of HL-60 growth and neutrophilic
differentiation in serum-containing and serum-free
media
HL-60 acute promyelocytic leukemia cells were grown in IMDM supplemented with
either 10% FBS or ITS supplement. A growth curve was constructed for cells grown in
both media by taking measurements for cell concentration every 12 hours for 5 days. Cell
viability was also assessed simultaneously and was consistently above 90% live cells for
IMDM-ITS cultured cells. IMDM-FBS cultured cells were also consistently above 90%
live cells except for the final measurement at 5 days after passaging when the viability
dropped to 87% while the number of cells was still increasing (Figure 6A). From an
initial seed concentration of 105 for cells culture in both media, the cell concentration of
the cultures steadily increased at all measurement times. After 120 hours had passed, the
IMDM-FBS cultured cells reached a final concentration of (1.93 ± 0.30) x106 cells/mL,
while the IMDM-ITS cultured cells reached a final concentration of (1.44 ± 0.72) x106
cells/mL (Figure 6B). The population doubling time was calculated using the doubling
time equation (Equation 1) found in section 2.2, considering two consecutive time points
within the log phase. The growth rate was not significantly different between IMDMFBS cells and IMDM-ITS cells which doubled in 22.3 ± 2.7 and 23.4 ± 4.9 hours
respectively (Figure 6C).
ATRA is a well characterized and widely used method of inducing granulocytic
differentiation of promyeloid cells. To assess the degree of differentiation of HL-60 cells,
a range of concentrations was used to treat HL-60 cells for 72 hours. Nuclear morphology
analysis of HL-60 cells treated with 1 M ATRA showed many segmented nuclei
characteristic of granulocytic differentiation (Figure 7A). IMDM-FBS cells that were
treated with 1 M ATRA were significantly more differentiated than untreated controls,
where 89.4% of cells displayed neutrophil-like nuclear morphology compared to 6.6% of
untreated cells (p < 0.0001) HL-60 cells grown in a serum-free culture showed a similar
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Figure 6. HL-60 cells grown in serum-containing and serum-free media show
similar growth and viability.
HL-60 cells were cultured in 60 mm suspension culture dishes at an initial concentration
of 105 cells/ml and were grown for 5 days in a humidified incubator set to 37oC and 5%
CO2. Every 12 hours, cell concentration and viability were recorded. Cell viability (A)
and concentration (semi-log scale) (B) are presented as the mean ± SD, n=3. The
population doubling time of HL-60 cells was calculated considering two consecutive
measurements within the log phase of the growth curve (C), mean ± SD, n=3. Significant
differences were determined using Student’s t-test. * p < 0.05
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Figure 7. Confirmation of ATRA-induced differentiation of HL- 60 cells by nuclear
morphology in the presence and absence of serum.
HL-60 cells were cultured in IMDM supplemented with 10% FBS, or with ITS
supplement and were induced to differentiate by the treatment of cells with vehicle
(CTRL), or 1 M ATRA for 72 hours. (A) HL-60 cell morphology (left panels) and
nuclei staining by DAPI (right panels). (B) Differentiation Index was determined as the
percentage of nuclei that displayed abnormal nuclear shape (black bars: serum containing
medium; grey bars; serum-free medium) (C). Scale bars represent 100 M (bright field)
and 20 M (fluorescence). The differentiation index was a dose dependent response and
is correlated negatively with cell viability. Significant differences were determined using
two-way ANOVA followed by Tukey’s HSD test and are represented as different letters,
considering p < 0.05.
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response to ATRA as 84.3% of cells displayed neutrophil-like nuclear morphology
relative to only 5.3% of untreated cells (p < 0.0001). The differentiation index did not
significantly differ between medium type for either treatment (Figure 7A-B). Initially, the
amount of differentiated cells was proportional to the concentration of ATRA used in
culture as ATRA concentrations between 0.01 and 0.1 M induced significantly more
differentiation step wise with each increase in concentration. However, a plateau was
reached at concentrations above 0.25 M, as the amount of differentiated cells was not
significantly different as all such concentrations (0.25, 0.5, 1.0, and 2.0 M ATRA)
induced a high level of differentiation (80.4, 83.7, 84.7, and 88.1 % respectively) (F7, 16 =
191.0, p < 0.0001). Cell viability was assessed with trypan blue (0.4%) and a
hemocytometer. ATRA concentration was inversely proportional to the cell viability
(Figure 7C). Interestingly, the significance pattern for the cell viability across different
ATRA concentrations was the opposite of that seen for the differentiation index. All
ATRA concentrations of 0.1 M or below were not statistically different however, for
each concentration above (0.25, 0.5, 1.0, and 2.0 M ATRA) the viability of cell cultures
was significantly less at each increasing concentration interval (F7, 16 = 58.47, p < 0.0001)
with the lowest viability (81%) seen at an ATRA concentration of 2.0 M (Figure 7C)
The expression of genetic biomarkers of differentiation was determined using RT-PCR
and RT-qPCR. HL-60 cells grown in both serum-supplemented and serum-free
conditions express significantly higher amounts of neutrophil specific genes in response
to 1 M of ATRA for 72 hours (Figure 8A). Semiquantitative analysis of endpoint RTPCR products separated on a 2% agarose gel show that NCF1 was upregulated 12.1-fold
in IMDM-FBS grown cells relative to untreated cells (p < 0.0001) and 60.5-fold in
IMDM-ITS grown cells relative to untreated cells (p < 0.0001) (Figure 8B). NCF2 was
upregulated 4.1-fold and 8.7-fold in IMDM-FBS and IMDM-ITS respectively after
treatment with 1 M ATRA for 72 hours (Figure 8C). The expression of the oncogenic
marker MYC was also investigated for its response to ATRA. Upon treatment with
ATRA, and subsequent differentiation, expression of this oncogene was determined by
RT-qPCR and was significantly decreased in both IMDM-FBS cells (22.4-fold, p <
0.001) and in IMDM-ITS cells (3.6-fold, p < 0.01) (Figure 8D).
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Figure 8. HL-60 cells fated to the granulocytic lineage express significantly more
neutrophil associated genes.
HL-60 cells were treated with vehicle (CTRL) or 1 M ATRA for 72 hours to induce
neutrophilic differentiation. (A) Expression of neutrophil specific genes NCF1 and NCF2
was assessed by RT-PCR and products were separated on a 2% agarose gel. (B-C)
Expression of NCF1 and NCF2 was quantified with a semi-quantitative method using
ACTB as an internal control. (D) Oncogenic marker of pluripotency MYC was quantified
using RT-qPCR with the Livak Method (2-Ct) using ACTB as an internal control (black
bars: serum-containing medium; grey bars: serum-free medium). Data are presented as
the mean ± SD, n=3-5. Significant differences were determined using two-way ANOVA
followed by Tukey’s HSD test and are represented as different letters, considering p <
0.05.
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Global O-GlcNAcylation was assessed by immunodot blot assay using the pan-specific
monoclonal antibody RL2 (Figure 9A). Densitometric analysis showed a significant
decrease in the O-GlcNAcylation (F1,8 = 110.3, p < 0.0001) of cytosolic proteins isolated
from differentiated cells relative to promyeloid cells (Figure 9B). This reduction in OGlcNAcylation was seen in both media types and was not significantly different between
the two types of media.

3.2 Galectins are differentially regulated in response to
ATRA-induced HL-60 differentiation in both serumcontaining and serum-free media
Genetic regulation of six galectins was assessed using RT-qPCR to compare their
expression between neutrophil-like cells and promyeloid stem-like cells. HL-60 cells
were grown in either a serum-containing medium, or a serum-free medium to assess the
effect of serum growth factors on galectin regulation. LGALS1 was significantly
downregulated after neutrophilic differentiation in both media (F1,8 = 379.3, p < 0.0001.)
The choice of medium had no effect on the down regulation of LGALS1 as cells grown in
both media showed a significant drop in LGALS1 mRNA after treatment with 1 M
ATRA (Figure 10A). Two-way ANOVA shows that three galectin genes LGALS3 (F1,8 =
243.8, p < 0.0001), LGALS10 (F1,8 = 522.9, p < 0.0001), and LGALS12 (F1,8 = 243.4, p <
0.0001) were significantly upregulated in HL-60 cells after neutrophilic differentiation.
Interestingly for LGALS10 (F1,8 = 477.8, p < 0.0001) and LGALS12 (F1,8 = 71.14, p <
0.0001), there were stronger inductions of these genes in serum-containing medium
whereas for LGALS3 (F1,8 = 0.1945, p > 0.05), there was no statistically significant effect
of medium type on the upregulation. The genetic expression of LGALS9 increased upon
ATRA treatment only in the serum-free medium (Figure 10D). Two-way ANOVA
showed that there was a significant increase in LGALS9 expression when cells were
treated with ATRA and grown in a serum-free medium (F1,8 = 9.094, p < 0.05), a pattern
opposite of that seen with LGALS10 and LGALS12. The expression of LGALS8 was
unaffected by both medium type and by treatment with ATRA (Figure 10C).
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Figure 9. Global O-GlcNAcylation as a biomarker of neutrophilic differentiation.
HL-60 cells grown in IMDM with (black bars) and without serum (grey bars) were
differentiated to neutrophil-like cells with 1 M ATRA for 72 hours and protein lysates
were assessed for O-GlcNAcylation using the RL2 antibody (A). Densitometric analysis
shows that the global O-GlcNAcylation is significantly decreased (p < 0.0001) regardless
of media supplement using two-way ANOVA followed by Tukey’s HSD test (B).
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Figure 10. Neutrophilic differentiation induced changes in the transcription of
galectin genes.
Ct for galectin mRNA transcript expression in HL-60 cells grown with (black bars)
and without serum (grey bars) after 72 hours treatment with 1 M ATRA relative to
vehicle-treated (CTRL) cells for both conditions were determined using RT-qPCR. (A)
LGALS1, (B) LGALS3, (C) LGALS8, (D) LGALS9, (E) LGALS10, and (F) LGALS12.
ACTB was used as an internal control. Data are presented as the mean ± SD, n=3-5.
Significant differences were determined using two-way ANOVA followed by Tukey’s
HSD test and are represented as different letters, considering p < 0.05.
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The differences of transcript expression were correlated with western blot analyses
(Figure 11A). Densitometric analysis of bands showed a significant decrease in the
expression of galectin-1 in either medium after treatment with ATRA (F1,8 = 44.85, p <
0.001), but that the medium used did not significantly affect the expression of galectin-1
(Figure 11B). No significant differences in the expression of galectin-9 were seen
between ATRA-treated and untreated cells (F1,8 = 3.642, p > 0.05), nor between serumcontaining and serum-free medium (F1,8 = 3.883, p > 0.05) (Figure 11D). Two-way
ANOVA determined that the expression of galectin-3 was significantly higher after
treatment with ATRA (F1,8 = 377.8, p < 0.0001) and was also higher in cells grown in a
serum-free medium (F1,8 = 72.59, p < 0.0001) (Figure 11C). The expression of galectin10 was also significantly higher in cells treated with ATRA (F1,8 = 333.9, p < 0.0001).
The expression of galectin-10 was also affected by the medium type, as seen by the
greater fold change in expression in the serum-containing medium (F1,8 = 3157.7, p <
0.0001) (Figure 11E).

3.3 Alterations in the O-GlcNAcylation homeostasis of HL60 cells affects the expression of galectins
HL-60 cells were treated with inhibitors of O-GlcNAc cycle related enzymes to
determine the role of O-GlcNAcylation in the granulocytic differentiation process of
promyeloid cells. Cell nuclei were stained with DAPI, and images were visually
inspected to assess the percent of cells displaying segmented nuclei characteristic of
neutrophilic differentiation (Figure 12A). Few untreated cells (5.4 % in IMDM-FBS,
6.6% in IMDM-ITS) had nuclear morphology characteristic of differentiation, suggesting
that spontaneous differentiation is rare. Inhibition of OGA with TG also had no
significant effect on the nuclear morphology, indicative of little to no differentiation
occurring. Inhibitors that lower the global O-GlcNAcylation by inhibiting either OGT or
GFAT induced changes in the nuclear morphology. With the inhibition of either of these
enzymes, there were higher percentages of differentiated cells as measured by nuclear
morphology relative to untreated cells. Inhibition of OGT by AC was associated with an
increase of the differentiated appearing cells which was statistically significant whereas
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Figure 11. Galectins are differentially regulated between differentiated neutrophillike cells and stem-like precursor HL-60 cells.
Immunoblots for galectins (A) in HL-60 cells grown with either 10% FBS (black bars),
or ITS supplement (grey bars), treated with vehicle (CTRL), or 1 M ATRA for 72
hours. Quantification of galectin-1 (B), galectin-3 (C), galectin-9 (D), and galectin-10 (E)
by densitometric analysis of immunoblots) by densitometric analysis with ImageLab
V6.0. -actin was used as a loading control for western blot. Data are presented as the
mean ± SD, n=3-5. Significant differences were determined using two-way ANOVA
followed by Tukey’s HSD test and are represented as different letters, considering p <
0.05.
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Figure 12. The disruption of the O-GlcNAc homeostasis alters the nuclear
morphology of HL-60 cell nuclei.
HL-60 cells were culture in IMDM supplemented with 10% FBS (black bars), or with
ITS (grey bars) supplement and were induced to differentiate by the treatment of cells
with vehicle (CTRL), 25 M AC, 10 M TG, or 12.5 M DON for 72 hours with daily
drug supplementation. (A) Nuclear morphology of treated and untreated cells were
visualized by DAPI staining. Scale bars represent 20 M. (B) Differentiation Index was
determined as the percentage of nuclei that displayed abnormal nuclear shape. Data are
presented as the mean ± SD, n=3-5. Significant differences were determined using twoway ANOVA followed by Tukey’s HSD test and are represented as different letters,
considering p < 0.05.
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GFAT inhibitor DON saw an even higher percent of differentiated nuclei (F3,16 = 64.02, p
< 0.0001), significantly more than both untreated cells and those cells treated with an
OGT inhibitor (Figure 12B).
All galectins expressed in HL-60 cells showed significantly altered expression levels
among various treatments disrupting the O-GlcNAc homeostasis. For both LGALS3 (F3,16
= 250.8, p < 0.0001) and LGALS8 (F3,16 = 60.06, p < 0.0001), there were significant
increases in the expression of these gene in cells treated with DON for 72 hours. The
medium used did not affect the expression of LGALS3 nor LGALS10 (Figure 13 B-C).
LGALS9 also showed no measurable difference between the two media used but did show
a significant increase in expression in cells treated with TG (F3,16 = 6.193, p < 0.01)
(Figure 13D). All other galectin genes were significantly altered in response to different
treatments and media types. LGALS1 expression was significantly increased in cells
treated with AC and DON (F3,16 = 446.6, p < 0.0001), and it was significantly higher in
DON-treated cells in serum-containing medium compared to serum-free medium (F1,16 =
90.13, p < 0.01) (Figure 13A). For both of LGALS10 (F3,22 = 5.063, p < 0.01) and
LGALS12 (F3,16 = 61.2, p < 0.0001), two-way ANOVA revealed significantly higher
expression of LGALS10 (Figure 13E) in response to DON treatment, while LGALS12
(Figure 13F) expression was significantly higher in both TG- and DON-treated cells.
However, the DON-induced increase in expression of LGALS10 (F1,16 = 14.33, p < 0.01),
was only seen in serum-containing medium. The TG and DON-induced increase in
expression of LGALS12 (F1,16 = 126.0, p < 0.0001) similarly was significantly higher in
cells grown in serum-containing medium.
The protein levels of galectins also showed changes when treated with O-GlcNAc cycle
enzyme inhibitors corresponding roughly to their genetic regulation (Figure 14A). The
expression of galectin-1 was significantly increased in response to DON-treatment (F3,16
= 7.042, p < 0.01), but only in serum-containing medium (F1,16 = 7.936, p < 0.05) (Figure
14B). The expression of galectin-9 was significantly decreased in response to DON- and
AC-treatment (F3,16 = 15.96, p < 0.0001), however, this decrease was only seen in serumcontaining medium with AC-treated cells (F1,16 = 5.326, p < 0.05) whereas galectin-9
expression was reduced in both media types upon treatment with DON (Figure 14D). The
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Figure 13. Galectin genes are differentially regulated by drugs disrupting the OGlcNAc cycle in serum-free vs serum-containing media.
Ct for galectin mRNA transcript expression in HL-60 cells grown with (black bars) or
without serum (grey bars) treated with either vehicle (CTRL), 25 M AC, 10 M TG, or
12.5 M DON for 72 hours with daily drug supplementation for both media was
determined using RT-qPCR. (A) LGALS1, (B) LGALS3, (C) LGALS8, (D) LGALS9, (E)
LGALS10, and (F) LGALS12. ACTB was used as an internal control. Data are presented
as the mean ± SD, n=3-5. Significant differences were determined using two-way
ANOVA followed by Tukey’s HSD test and are represented as different letters,
considering p < 0.05.
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Figure 14. Galectins are differentially regulated by drugs disrupting the O-GlcNAc
cycle in a serum-containing media.
Immunoblots for global O-GlcNAcylation by pan-specific RL2 monoclonal antibody in
(A) HL-60 cells grown with either 10% FBS, or ITS supplement, treated with either
vehicle (CTRL), 25 M AC, 10 M TG, or 12.5 M DON for 72 hours with daily drug
supplementation relative to untreated cells. Quantification of galectin-1 (B), galectin-3
(C), galectin-9 (D), and galectin-10 (E) by densitometric analysis of immunoblots with
ImageLab V6.0. -actin was used as a loading control for western blot. Data are
presented as the mean ± SD, n=3-5. Significant differences were determined using twoway ANOVA followed by Tukey’s HSD test and are represented as different letters,
considering p < 0.05.
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protein expression of galectin-3 and galectin-10 displayed similar patterns to each other.
DON treatment resulted in significantly higher expression of both galectin-3 (F3,17 =
26.27, p < 0.0001) and galectin-10 (F3,16 = 59.68, p < 0.0001) (Figure 14B, D), as did
AC-treatment, but only in cells grown in serum-containing medium for both galectin-3
(F1,17 = 34.49, p < 0.0001) and galectin-10 (F1,16 = 15.83, p < 0.01). Furthermore, the
protein fold change in the expression of galectin-10 after DON-treatment was also
significantly higher in cells grown in a serum-containing media.
To confirm the action of drugs disrupting the O-GlcNAc cycle, global O-GlcNAcylation
was assessed by western blot analysis using the RL2 antibody (Figure 15A). Treatment
with AC significantly reduced O-GlcNAcylation relative to untreated cells in a manner
comparable to ATRA-treated cells, while DON-treated cells showed a much stronger
reduction in O-GlcNAcylation. Cells treated with TG had many more O-GlcNAcylated
proteins relative to all other treatment groups (F4,20 = 188.9, p < 0.0001). The effects of
drugs that disrupt the O-GlcNAc cycle enzymes exhibit their effects regardless of the
medium type as there was no significant difference between these media types (Figure
15B).

3.4 Effects of ATRA and O-GlcNAc cycle inhibitors on the
secretion of galectins from HL-60 cells
A previous study by Asiamah et al. (2018) indicated that galectins are contained within
bovine serum products. As such, only cells cultured in a serum-free medium were used to
assess the secretion of galectins in order to eliminate background galectins from the
cultured medium. Cell culture supernatants were collected and tested for the extracellular
concentrations of galectin-1, galectin-3, and galectin-9 using ELISA. There was only a
significant increase in the extracellular galectin-1 concentration in cultures of cells
treated with DON (F4,10 = 33.53, p < 0.0001) (Figure 16A). With regards to both galectin3 (F4,24 = 10.12, p < 0.0001) and galectin-9 F4,10 = 41.16, p < 0.0001, there were
significant increases in the secretion of these proteins when treated with either ATRA or
DON compared to all other treatments for both proteins (Figure 16B-C). Surprisingly, the
OGT inhibitor AC although very potent in its ability to reduce O-GlcNAcylation of
intracellular proteins, did not significantly increase the secretion of any galectins assayed
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Figure 15. Global O-GlcNAcylation is perturbed by drugs targeting O-GlcNAc cycle
enzymes in HL-60 cells grown with and without serum.
Immunoblots for global O-GlcNAcylation by pan-specific RL2 monoclonal antibody in
(A) HL-60 cells grown with either 10% FBS, or ITS supplement, treated with either 1
M ATRA, 25 M AC, 10 M TG, or 12.5 M DON for 72 hours with daily drug
supplementation relative to untreated cells. Quantification of O-GlcNAcylation was
determined by the integral intensity of bands within each individual lane by densitometric
analysis of immunoblots. Quantification of O-GlcNAcylated proteins (G) by
densitometric analysis with ImageLab V6.0. -actin was used as a loading control for
western blot. Data are presented as the mean ± SD, n=3-5. Significant differences were
determined using two-way ANOVA followed by Tukey’s HSD test and are represented
as different letters, considering p < 0.05.
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Figure 16. The secretion of galectins is related to the O-GlcNAc status of the cell.
The extracellular galectin concentrations for Gal-1, Gal-3, and Gal-9 were assessed for
HL-60 cells grown with ITS treated with either vehicle (CTRL), 1 M ATRA, 25 M
AC, 10 M TG, or 12.5 M DON for 72 hours with daily drug supplementation relative
to untreated cells was determined using ELISA. The concentration (ng/mL) of galectins 1, -3, and -9 (A-C) found in the cell culture supernatant varied among treatments. The
extracellular galectins were quantified by densitometric analysis of immunoblots (D).
The relative intensities of antibody signals were normalized to untreated HL-60 cells and
normalized to the cell concentration (E-H). Data are presented as the mean ± SD, n=3-5.
Significant differences were determined using one-way ANOVA followed by Tukey’s
HSD test and are represented as different letters, considering p < 0.05.
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by ELISA. Extracellular proteins from HL-60 cell culture supernatants were immobilized
on nitrocellulose membranes and blotted for galectins (Figure 16 D). The secretion of
galectin-1 (F4,10 = 50.47, p < 0.0001), galectin-3 (F4,10 = 313.1, p < 0.0001), galectin-9
(F4,10 = 111.4, p < 0.0001), and galectin-10 (F4,10 = 39.80, p < 0.0001) were significantly
increased in response to ATRA and DON treatments for all galectins (Figure 16E-H).

3.5 Reduction of O-GlcNAc in HL-60 cells leads to PMAinduced generation of H2O2 in both serum-containing
and serum-free media
Granulocytic differentiation of HL-60 cells resulted in the expression of proteins that
comprise the NADPH-oxidase complex which is responsible for the production of
hydrogen peroxide. Differentiation of HL-60 cells into neutrophil-like cells in a serumcontaining medium was confirmed in both ATRA and DON treatments for 72 hours (F4,10
= 464.7, p < 0.0001) by the high relative expression of NCF1 (Figure 17A). In the
absence of serum in the growth medium, ATRA and DON treatments similarly show
significant increased expression of NCF1 (F4,10 = 222.8, p < 0.0001) (Figure 17 B).
The upregulation of neutrophil-associated biomarkers of differentiation corresponded to
the increased production of hydrogen peroxide via the NADPH oxidase complex.
Hydrogen peroxide production was induced by PMA exposure and was measured by the
reduction of scopoletin fluorescence. HL-60 cells treated with ATRA or DON oxidized
scopoletin faster than untreated cells and reached minimal fluorescence before then end
of the time trace (Figure 17 C-D). The rate of hydrogen peroxide production was
calculated using RStudio V4.0.5 software and all measurements were normalized to the
ATRA positive control. HL-60 cells treated with DON produced hydrogen peroxide upon
induction by PMA at rates not significantly different than the ATRA positive control in
both serum-containing (F4,18 = 17.42, p < 0.0001) and serum-free (F4,18 = 21.88, p <
0.0001) media (Figure 17 E-F). In both media, the cells treated with ATRA or DON
produced more hydrogen peroxide than cells treated with other drugs or untreated cells as
there was no significant difference in the rates of hydrogen peroxide production in cells
treated with TG or AC from untreated, stem-like promyeloid cells.
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Figure 17. H2O2 production via NADPH oxidase activity is a key component of
neutrophilic pathogen response.
The relative expression of NCF1 transcript abundance for serum-containing and serumfree HL-60 cells treated with vehicle (CTRL), 1 M ATRA, 25 M AC, 10 M TG, or
12.5 M DON for 72 hours with daily drug supplementation was determined using RTqPCR considering ACTB as a housekeeping gene (A-B). The oxidation of scopoletin
occurs in the presence of hydrogen peroxide and is determined by a decrease in
fluorescence over time (C-D). Rate of H2O2 production (standardized to fold expression)
as a measure of cellular differentiation, induced by the PKC activator PMA, in HL-60
cells. Data are presented as the mean ± SD, n=5. Significant differences among
treatments were determined using one-way ANOVA followed by Tukey’s HSD test and
are represented as different letters considering p < 0.05.
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3.6 Correlative analysis validates galectins and OGlcNAcylation as biomarkers of cell differentiation
To identify a specific correlation between galectins, global O-GlcNAcylation, and
cellular differentiation, a Pearson’s correlation was conducted based on treatments with
25 M Ac-5sGlcNAC, 10 M thiamet G, and 12.5 M 6-diazo-5-oxo nor -L-leucine.
Pearson’s correlation measures the strength of linear association between two variables,
in this case relative gene expression. NCF1 and MYC were used as positive and negative
markers of neutrophilic differentiation of HL-60 cells. The quantification of
chemiluminescent signal produced by western blot with the RL2 primary antibody
recognizing O-GlcNAcylated proteins measures the relative global O-GlcNAcylation.
The Pearson’s correlation test showed a significant negative correlative between global
O-GlcNAcylation and the expression of three galectin genes: LGALS1 (p < 0.0001, R2 =
0.6427, n = 24), LGALS3 (p < 0.0001, R2 = 0.6624, n = 24), and LGALS8 (p < 0.0001, R2
= 0.5977, n = 24) (Figure 18 A-C).
A Pearson’s correlation test was also used to determine how markers of neutrophilic
differentiation were correlated with the expression of galectin genes. With respect to the
neutrophil specific marker NCF1, two genes showed a significant positive relationship
with NCF1 expression, those being LGALS1 (p < 0.001, R2 = 0.4137, n = 24), LGALS3 (p
< 0.0001, R2 = 0.8406, n = 24), and LGALS8 (p < 0.0001, R2 = 0.8033, n = 24) (Figure 19
A-C). The oncogenic marker MYC is associated with the maintenance of stem-like
features in HL-60 cells. Five galectins showed significant negative correlation with
expression of MYC: LGALS1 (p < 0.0002, R2 = 0.7236, n = 24), LGALS3 (p < 0.0001, R2
= 0.5490, n = 24), LGALS8 (p < 0.001, R2 = 0.4475, n = 24), LGALS10 (p < 0.05, R2 =
0.1723, n = 24), LGALS12 (p < 0.05, R2 = 0.1779, n = 24) (Figure 20 A-C, E, F).
A final correlation analysis was conducted to assess the relationship between global OGlcNAcylation and the expression of biomarkers NCF1 and MYC. NCF1 is significantly
negatively correlated with global O-GlcNAcylation (p < 0.001, R2 = 0.4897, n = 24).
Whereas MYC showed a significant positive correlation with global O-GlcNAcylation (p
< 0.0001, R2 = 0.6676, n = 24) (Figure 21 A-B).
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Figure 18. Correlation in transcript levels between galectins and relative global OGlcNAcylation (RL2).
Relative global O-GlcNAcylation of intracellular proteins in HL-60 cells measured using
semi quantitative Western blot analysis, plotted against Ct for galectin genes. HL-60
cells were treated with 25 M AC (■), 10 M TG (▲), 12.5 M DON (★) or vehicle
(CTRL) (●). A) LGALS1, (B) LGALS3, (C) LGALS8, (D) LGALS9, (E) LGALS10, (F)
LGALS12. ACTB was used as an internal control. Significant correlation between genes
and global O-GlcNAcylation was determined using the Pearson’s correlation test and a
threshold set at p < 0.05.
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Figure 19. Correlation in transcript levels between galectins with neutrophil specific
genetic biomarker NCF1.
Ct of neutrophil specific genetic biomarker NCF1, plotted against Ct galectin
genes. HL-60 cells were treated with 25 M AC (■), 10 M TG (▲), 12.5 M DON (★)
or vehicle (CTRL) (●). (A) LGALS1, (B) LGALS3, (C) LGALS8, (D) LGALS9, (E)
LGALS10, (F) LGALS12. ACTB was used as an internal control. Significant correlation
between genes and global O-GlcNAcylation was determined using the Pearson’s
correlation test and a threshold set at p < 0.05.
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Figure 20. Correlation in transcript levels between galectins with oncogenic
biomarker of cell pluripotency MYC
Ct of oncogenic biomarker of cell pluripotency MYC, plotted against Ct galectin
genes. HL-60 cells were treated with 25 M AC (■), 10 M TG (▲), 12.5 M DON (★)
or vehicle (CTRL) (●). (A) LGALS1, (B) LGALS3, (C) LGALS8, (D) LGALS9, (E)
LGALS10, (F) LGALS12. ACTB was used as an internal control. Significant correlation
between genes and global O-GlcNAcylation was determined using the Pearson’s
correlation test and a threshold set at p < 0.05.
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Figure 21. The correlation between O-GlcNAcylation and neutrophilic
differentiation.
Relative global O-GlcNAcylation of intracellular proteins in HL-60 cells measured using
semi quantitative Western blot analysis, plotted against Ct for genetic markers of
differentiation. HL-60 cells were treated with 25 M AC (■), 10 M TG (▲), 12.5 M
DON (★) or vehicle (CTRL) (●). (A) NCF1, (B) MYC. ACTB and its protein -actin
were used as housekeeping controls for RT-qPCR and Western blots, respectively.
Significant correlation between genes and global O-GlcNAcylation was determined using
the Pearson’s correlation test and a threshold set at p < 0.05.
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Chapter 4

4

Discussion

The findings of my research demonstrate that galectins are involved in neutrophilic
differentiation of HL-60 promyeloid leukemia cells and that this is an O-GlcNAc
sensitive relationship. The first objective showed that HL-60 cells readily differentiate to
the granulocyte lineage upon stimulation with ATRA both in the presence of, and
absence of serum factors. This was confirmed morphologically by examining the
segmentation of nuclei, and genetically by the expression of associated biomarkers or, by
lack of expression of markers associated with the stem-like precursor cells. The second
objective verified the expression profile of galectins, the genetic changes of neutrophil
associated genes, and functional activity of neutrophil like cells. RT-qPCR, western blot,
and the NADPH-oxidase functional assay were used to construct a profile to characterize
the neutrophil. Galectins -3 and -10 were identified as inducible by the differentiation
stimulus. In my third objective, I modulated the global O-GlcNAcylation of HL-60 cells
with biochemical inhibitors of enzymes in the O-GlcNAc cycle to compare to the profile
of neutrophils as per objective two and verify the link between O-GlcNAcylation and
neutrophilic differentiation. Reduction of global O-GlcNAcylation resulted in increased
expression of galectin-3 and galectin-10, consistent with changes that were observed in
ATRA-induced differentiation as well as increased expression of neutrophil specific
genetic marker NCF1. The similar changes in the expression of neutrophil markers,
galectin expression profiles, and reduction in global O-GlcNAcylation suggest that
granulocytic differentiation is achievable by targeting either the canonical differentiation
pathway or the hexosamine biosynthesis pathway. I also revealed that granulocytic
differentiation of HL-60 cells induced by either ATRA, or DON was accompanied by
increased secretion of galectins and decreased O-GlcNAcylation of intracellular proteins.
As such, my experimental findings confirm a novel concept of O-GlcNAc-mediated
regulation of endogenous and exogenous networks of galectins in the context of cellular
differentiation.
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4.1 Interpretation
4.1.1 Neutrophilic differentiation is achieved with and without serum,
altering galectin expression in the process
The use of ATRA as a differentiation agent has long been used in research and in clinical
treatment of APL (Drach et al., 1993; Johnson and Redner, 2015). Terminal
differentiation is a treatment for cancer because the mature leukocytes lose their infinite
proliferative capacity due to genetic changes resulting in the loss of signaling through
pathways that drive the cell to mitosis (Chaplinski et al., 1986; Mollinedo et al., 1998).
HL-60 cells were grown in both serum-containing and serum-free media, supplemented
with ITS to keep cells proliferative, to assess what if any impact serum has on the
terminal differentiation of HL-60 cells and what effect this may have on galectin
expression profiles. HL-60 cells grow at approximately the same rate regardless of media
supplement, and differentiation is easily induced by ATRA in both cases as well.
O-GlcNAcylation is a marker of differentiation. Highly abundant in cancerous precursor
cells, the O-GlcNAcylation is significantly reduced in cells which have been terminally
differentiated by ATRA. Differentiation down regulates the IR which is necessary for
glucose metabolism (Chaplinski et al., 1986). Cancer cells make liberal use of the
Warburg effect (Ferrer et al., 2014; Akella et al., 2020), preferentially producing energy
through glycolysis rather than through oxidative phosphorylation and the electron
transport chain (Cervantes-Madrid et al., 2015). The increased flux through pathways,
which are offshoots of glycolysis, such as the PPP (Patra and Hay, 2014) and the HBP
(Asthana et al., 2018), result from this. Reductions of global O-GlcNAcylation have
previously been reported in HL-60 granulocyte differentiation (Asthana et al., 2018) and
result in lowered flux through the PPP (Rao et al., 2013) negatively regulating cell
growth and proliferation. We show here that the interplay between protein OGlcNAcylation and granulocytic differentiation is unaffected by the presence or absence
of serum in HL-60 cell culture.
The expression of some galectins is induced by ATRA-induced differentiation whereas
other galectins are suppressed. While some galectins displayed increased expression after
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differentiation, like LGALS3, LGALS10, and LGALS12, others remain either unaffected,
like LGALS8 and LGALS9, while one galectin showed significant reduction in transcript
abundance, namely LGALS1. While the existence of many galectins with similar structure
and functionality suggests an evolutionary redundance, clearly not all galectins are the
same and preform the same function and do so in the same cell types. The trends
exhibited in the induction or suppression of galectins were not affected by the presence of
absence of serum in the growth media. Markers of granulocyte differentiation such as
increased expression of NCF1 and NCF2, reduced O-GlcNAcylation, and NADPHoxidase H2O2 production were also induced regardless of serum supplementation
consistent with previous studies detailing granulocyte differentiation in a serum-free
model (Breitman et al., 1980b). The changes in galectin expression profiles both in the
presence and absence of serum indicate that galectins can be used as biomarkers of
differentiation.
Galectin-1 was significantly downregulated during ATRA-induced neutrophilic
differentiation. This differs from previous studies which used DMSO as a differentiation
agent and reported an upregulation of galectin-1 (Abedin et al., 2003; Vinnai et al.,
2017). However, it has also been reported that ATRA can induce a downregulation of
galectin-1 in HL-60 cells (Vakrushev et al., 2019). Chiarotti et al. (1994) also reported a
decrease in galectin-1 gene expression upon treatment with ATRA although this was in a
thyroid cell model. The results of this study confirm retinoic acid-induced suppression of
LGALS1 expression as has been previously reported. Taken together, this suggests a
differential regulation for LGALS1 using different induction agents.
Galectin-3 was significantly upregulated during neutrophilic differentiation. This is
consistent with previous literature (Abedin et al, 2003; Vinnai et al., 2017). Galectin-3
has been widely studied in neutrophil models and has many reported functions including
stimulating superoxide production (Yamaoka et al., 1995), promoting neutrophil adhesion
to laminin (Kuwabara et al., 1996), and promoting neutrophil extravasation (Sato et al.,
2002). Here, we show that galectin-3 is upregulated when cells are induced to neutrophils
by ATRA, similar to observations in previous studies which used DMSO as a
differentiation agent (Abedin et al., 2003; Vinnai et al., 2017). The consistency of
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galectin-3 upregulation in response to two different agents implicates galectin-3 as an
important protein in neutrophil functions and unlike galectin-1 is upregulated by both
ATRA and DMSO, making galectin-3 a good marker of differentiation.
LGALS10 was significantly upregulated in response to ATRA treatment. PU.1 is a known
transcription factor (Nowak et al., 2009) upregulated during granulocyte differentiation.
Dyer and Rosenberg (2001) reported a PU.1 binding site in the promoter region of the
LGALS10 gene. Galectin-10 was upregulated in cells fated to the neutrophilic lineage.
Previous literature (Dvorak and Ishizaka, 1995; Dyer and Rosenberg, 2001) reported high
galectin-10 expression in eosinophils and basophils, particularly in eosinophils where the
galectin-10 protein comprises up to 7-10% of eosinophil protein content (Dvorak et al.,
1998). As high galectin-10 expression is reported in other leukocytes, it is unsurprising to
see high expression in neutrophils which are leukocytes similar to eosinophils and
basophils, and indeed, this has been reported, albeit sparingly, in the literature (Vinnai et
al., 2017). Galectin-10 is under the transcriptional control of two PU.1 binding sites in the
promoter region (Dyer and Rosenberg, 2001). PU.1 is a transcription factor upregulated
during neutrophilic differentiation driving the cell towards terminal differentiation (Yan
et al., 2016). Although a difference in the magnitude of induction was seen between HL60 cells treated with or without serum (Figure 10E) the promoter region as reported
elsewhere does not contain anything resembling a serum response element leaving this
difference in induction unexplained (Dyer and Rosenberg, 2001).
The expression profile for galectin-12 was assessed only on the genetic level by use of
RT-qPCR. The galectin-12 gene, LGALS12, has previously been studied by our lab
(Vinnai et al., 2017) in the context of DMSO-induced neutrophilic differentiation. We
however used ATRA to induce neutrophilic differentiation. The increased transcript
abundance of LGALS12 seen upon differentiation by ATRA is at odds with previous
research (Xue et al., 2016) which reported that inhibition of LGALS12 by a doxycycline
induced knockdown of LGALS12 enhanced ATRA-induced differentiation. However,
while Xue et al. (2016) showed that LGALS12 knockdown increased differentiation
markers by producing more ROS through the NADPH oxidase complex, they showed
that cells with wildtype LGALS12 expression also displayed significantly higher levels of
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neutrophilic biomarkers even in the presence of LGALS12. The researchers did not assess
the galectin expression profile among differentiation status by RT-qPCR and to my
knowledge there are no papers which report the changes in LGALS12 expression in such
a model with ATRA specifically. This suggests that LGALS12 does not need to be
inhibited in order to induce differentiation. The expression of LGALS12 was decreased in
DMSO-treated HL-60 cells (Figure S1) which is consistent with previous reports using
DMSO as a differentiation agent. Yang et al. (2001) reported that galectin-12 expression
was upregulated in cells experiencing cell cycle arrest. This may be consistent with my
results wherein cells that had inhibited growth and proliferation by ATRA or DON, in
both cases increased their expression of galectin-12. This group also show that
transfection with galectin-12 increased the proportion of cells arrested at the G1 phase.
Galectin-12 transfected cells showed higher proportions of cells arrested at the G1 phase
even in the presence of nocodazole (Yang et al., 2001), a drug which arrests cells in the
M phase by disrupting spindle pole formation (Agami and Bernards, 2000) demonstrating
that that growth is arrested at G1 rather than there being an accelerated transition from M
to G1 (Yang et al., 2001). These results may be consistent with the observation of this
study which showed that galectin-12 is more highly expressed in differentiated cells
which have slowed growth rates knowing that differentiated cells arrest their growth and
proliferation concurrently with differentiation (Asthana et al., 2018). Indeed, galectin-12
could be a marker of neutrophilic differentiation, although the differential expression
between DMSO-induced neutrophils and ATRA-induced neutrophils suggests that
upregulation of galectin-12 may not be essential for growth arrest. These results in
combination with previous findings (Yang et al., 2001) suggest that growth arrest in
DMSO-induced neutrophils is likely triggered through a different mechanism.
Increased activity of the HBP is observed in all AML subtypes (Melnick and Licht, 1999;
Asthana et al., 2018) however, the APL fusion protein that allows for ATRA induced
differentiation is found only in the M3 subtype (Johnson and Redner, 2015). As
demonstrated by pervious research and in my research, the targeting of the HBP is an
effective method of inducing differentiation of HL-60 cells, suggesting a potential for
therapies targeting this pathway in the other subtypes of AML which are unable to be
induced by ATRA to terminally differentiate. Hyper-O-GlcNAcylation is hypothesized to
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keep cells in an undifferentiated state (Asthana et al., 2018; Zhang et al., 2018). Previous
literature showed that a differentiation agent administered in conjunction with an OGA
inhibitor like TG could reduce the proportion of differentiated cells (Zhang et al., 2018).
This shows how important the O-GlcNAc homeostasis is in the differentiation process of
HL-60 cells. Zhang et al. (2018) also demonstrated this O-GlcNAc dependent regulation
in the erythroid linage of the hematopoietic stem cell linage.

4.1.2 Inhibition of global O-GlcNAcylation induced the expression of
biomarkers of neutrophilic differentiation and altered galectin
expression.
O-GlcNAcylation is a dynamic post-translational modification implicated in the
regulation of many diseases such as diabetes (Akimoto et al., 2007), Alzheimer’s (Yuzwa
et al., 2014), Parkinson’s (Yuzwa et al., 2014) and cancer (Shi et al., 2010; Yi et al.,
2012). The modification is controlled by only two enzymes, OGT and OGA which add
and remove the GlcNAc moiety, respectively. Many reports show aberrant OGlcNAcylation in cancer (Shi et al., 2010; Asthana et al., 2018). As this is controlled by
only two enzymes and the precursor molecule is produced only by the HBP, manipulation
of the O-GlcNAc homeostasis is easily achieved in cell culture by chemical inhibitors,
and by RNA interference techniques (Perez-Cervera et al., 2013; Ferrer et al., 2014).
Here I used biochemical inhibition of O-GlcNAc cycle enzymes to determine the
relationship between differentiation, O-GlcNAcylation, and galectin expression.
DON is a powerful GFAT inhibitor which limits the availability of UDP-GlcNAc, the
precursor substrate necessary for O-GlcNAcylation. Following a protocol established by
Asthana et al. (2018), I showed an over 90% decrease in the chemiluminescent signal
detectable by the O-GlcNAc specific antibody RL2. This O-GlcNAc cycle enzyme
inhibitor very effectively induced neutrophilic differentiation as assessed by all but one
measure used in this study, namely the segmented nuclei assessed by DAPI staining. All
other markers of differentiation, NCF1, H2O2 production by PMA-induced NADPHoxidase activity, and galectin secretion were significantly increased when this drug was
used, and these results follow the same pattern as ATRA induced differentiation. Death
of AML cells was preceded by differentiation as has also been described elsewhere
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(Asthana et al., 2018). This suggests that terminal differentiation in addition to mitigating
the infinite proliferative capacity of AML cells also serves to kill these cells making
HBP-targeting therapies excellent candidates for potential future chemotherapeutics.
Surprisingly, the OGT inhibitor AC did not induce any of the markers of differentiation.
Although AC was a good inhibitor of OGT as indicated by the reduction of RL2 signal,
which was comparable to ATRA treatments, there was no upregulation of NCF1, no
H2O2 production, and the galectin secretion was not significantly increased by this drug.
Previous reports suggest that inhibition of OGT should induce neutrophilic
differentiation, as previously those groups using OSMI-1 (Asthana et al., 2018) and
alloxan (Ding et al., 2018), both of which are OGT inhibitors albeit with some off target
effects and with more cytotoxic effects, were able to show at least some upregulation of
biomarkers associated with differentiation.
The inhibition of cell growth was most prominently seen in HL-60 cells treated with the
GFAT inhibitor DON. UDP-GlcNAc is an important and widely used biomolecule in
cells, being a precursor for the production of proteoglycans, glycolipids and
glycoproteins (Grønning-Wang et al., 2011). Rao et al. (2015) showed that G6PD, an
enzyme in the PPP, must be glycosylated to allow flux through the pathway. The PPP is
vital to meet the demands for anabolic biosynthesis and provided antioxidant defense
(Patra and Hay, 2014). Mitotic arrest like what was seen in my research is explained by
the decreased flux through this PPP, which limited the de novo synthesis of DNA and
RNA as the PPP produces ribose-6-phospahte, a necessary precursor for nuclei acid
synthesis (Rao et al., 2015). The lack of necessary UDP-GlcNAc substrate for OGlcNAcylation of G6PD would be expected to lead to the results seen in my study. This
differs from ATRA- and DMSO-induced differentiation wherein the growth arrest of HL60 cells when induced by ATRA or DMSO takes days to occur (Mollinedo et al., 1998)
and this is supported by my observations that the cell concentration did increase over the
72-hour treatment frame, albeit the growth was slower than untreated cells (Table S1).
However, the growth arrest in DON-treated HL-60 cells was near-immediate as the
number of cells in culture over 72 hours was almost the same as the number of cells
before the treatment (Table S1). It seems to be the case that induction of genes involved
in differentiation precedes the growth arrest observed in ATRA- and DMSO-induced
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differentiation, but with the DON treatments, this linearity of occurrences doesn’t appear
obvious. Growth arrest preceding differentiation also was reported by Soddu et al. (1994)
who recovered wild-type p53 expression in HL-60 p53-null cells and consequently
reported granulocytic differentiation. The reassertion of cell cycle controls could be a
contributing factor to the observed differentiation. Cell growth arrest by O-GlcNAc
inhibition was also reported by (Li et al., 2017) who showed that inhibitors of OGlcNAcylation had effects on other post-translational modifications, specifically they
noted that reduced O-GlcNAcylation led to reduced phosphorylation of vimentin at Ser71, a vital modification for severing the vimentin filaments during cytokinesis which
resulted in failed cytokinesis. Indeed, it appears that O-GlcNAc is implicated in many
key pathways and processes of normal cellular function and that targeting the O-GlcNAc
pathway and regulation of O-GlcNAc in vitro impacts many of these cellular processes,
dysregulating them, with negative side effects on cell growth and proliferation (Rao et al.,
2015; Martinez et al., 2017; Asthana et al., 2018). It remains uncertain if the effects of
reduced O-GlcNAcylation on any of these pathways and processes can be rescued by the
“reactivation” of any given one of the dysregulated pathways.
Galectin-3 and galectin-10 were both upregulated in response to global O-GlcNAcylation
reduction just as they were in response to ATRA-induced neutrophilic differentiation. We
showed that inhibition of the HBP by DON significantly reduced the global OGlcNAcylation of HL-60 cells even more than was observed using ATRA. We also
showed that targeting the HBP induced neutrophilic differentiation by increasing the
expression of NCF1 and inducing H2O2 production by NADPH oxidase activity,
characteristic of neutrophil-like cells. Galectins-3 and -10 can therefore be viewed as
differentiation markers in neutrophilic models due to their similar upregulation using
different agents. There is also a similar trend of increased galectin-12 expression in
response to DON as was seen with ATRA. These results similarly suggest a role for
galectin-12 in neutrophilic differentiation and neutrophil function. This result too, is
consistent with Yang et al. (2001) who reported an association between galectin-12 and
cell cycle arrest at the G1 phase. DON almost immediately induced growth arrest as
evidenced by the minimal increase in cell concentration after 72 hours of treatment with
DON (Table S1). It is possible that the increased galectin-12 expression is related to the
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slower growth induced by both DON and ATRA, however the DMSO-induced
neutrophilic differentiation which resulted in decrease galectin-12 expression (Vinnai et
al., 2017) is inconsistent with my findings.
Galectin-8 expression was consistently high in HL-60 cells across all differentiating
treatments used, showing significantly increased expression in cells treated with DON
(Figure 13C). Galectin-8 plays a key role in neutrophil migration (Nishi et al., 2003).
While the results of this study demonstrate that galectin-8 is highly expressed among all
treatments, it only increased upon treatment with DON. The function that galectin-8 plays
in mediating neutrophil function is reported as being dependent on interaction with
neutrophilic markers of differentiation, such as CD11b also known as integrin M (Nishi
et al., 2003). Indeed, it appears that galectin-8 shows constitutive expression among cells
belonging to different differentiation states of the myeloid lineage, waiting for the
expression of its binding partners to mediate its function (Nishi et al., 2003).
Galectin-9 transcript abundance remained relatively constant across all treatments in all
experiments, consistent with previous literature (Vinnai et al., 2017; Abedin et al., 2003).
However, the intracellular protein levels decreased in treatments with ATRA, AC, and
DON, all of which significantly reduce the global O-GlcNAcylation of intracellular
proteins. While this might suggest some proteasomal degradation associated with
differentiation or reduced O-GlcNAcylation, I do not consider this to be the case as the
concentration of galectin-9 detected in cell culture supernatants was significantly
increased in those treatments as well. These observations suggest that galectin-9
expression is constitutive in HL-60 cells among varying differentiation states and stress
states, and that galectin-9 is preferentially secreted in differentiated cells and nutrient
stressed cells, suggesting that localization and function are affected by the treatments, not
the expression itself. Galectin-9 is well studied in its relationship to Tim-3. The binding
of galectin-9 and Tim-3 was demonstrated to be essential for the growth of leukemic cells
(Kikushige et al., 2015). I showed that HL-60 cells express galectin-9 at both the mRNA
and protein level. Other researchers (Gonçalves Silva et al., 2015; Prokhorov et al., 2015)
reported that galecin-9 interaction with Tim-3 triggers signaling pathways involving the
activation of phosphatidylinositol-3-kinase and downstream mTOR activity which signals
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cell growth and proliferation (Gibbs et al., 2011). The results of the present study are
consistent with these previous findings. Indeed, as the galectin-9 protein appears to be
preferentially secreted by cells that have undergone differentiation, suggestive of reduced
signaling through the mTOR pathway explaining the growth arrest in HL-60 cells treated
with ATRA or DON.

4.1.3 Differentiated HL-60 cells secreted more galectins than
precursor cells.
The secretion of galectins was assessed only in cells grown in a serum-free culture media.
Galectins are widely reported as signaling molecules present in serum in many models
from human to mouse to cow (Tribulatti et al., 2007; He et al., 2017; Asiamah et al.,
2018; Asiamah et al., 2019; Asiamah et al., 2020). In the supplemental material, I show
that using galectin antibodies specific to human galectins, I was able to detect these
galectins in the unconditioned IMDM+10% FBS medium and was unable to do the same
in the serum-free ITS-supplemented IMDM (Figure S2). To eliminate the background
detection of galectins for the purpose of ensuring that any galectin detection in the
extracellular environment was due to secretion from HL-60 cells, we adapted the serumfree culture method pioneered by the Breitman group in the 1980s (Breitman et al.,
1980b).
HL-60 cells induced to the granulocyte lineage by ATRA secreted significantly more of
all tested galectins compared to precursor stem-like cells. Interestingly, the increased
secretion of galectins from HL-60 cells was also achieved using a GFAT inhibitor DON.
DON was by far the most powerful drug in terms of reduction of O-GlcNAcylated
proteins as assessed by both western blot and dot blot assays. The ELISA data showed
that DON-treated HL-60 cells secreted significantly more galectin-1, galectin-3, and
galectin-9. These neutrophil-like cells induced by DON display galectin expression and
secretion trends similar to ATRA-treated HL-60 cells. Extracellular galectin-3 is an
important regulator of neutrophil function, acting both with and independently of
immunoglobin E to stimulate superoxide production via NADPH oxidase activity
characteristic of phagocytes (Hsu et al., 1992; Herrmann et al., 1993; Yamaoka et al.,
1995; Sundqvist et al., 2018). Secreted galectin-3 also promotes neutrophil phagocytosis
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of pathogens (Kohatsu et al., 2006; Linden et al., 2013) and non-pathogens (Fernández et
al., 2005). ROS production is also inducible by galectins-8 and -9. Galectin-8 stimulates
ROS production through the C-terminal domain (Nishi et al., 2003; Nishi et al., 2006)
whereas galectin-9 accomplishes this through a Tim-3 independent pathway (VegaCarrascal et al., 2014; Steichen et al., 2015). Extracellular galectin-10 is well
characterized in eosinophil models (Chua et al., 2012), but the roles in neutrophils and
when secreted by neutrophils is not well described in the literature. However, galectin-10
has been shown to drive IL-1 production in macrophages which results in neutrophil
accumulation (Rodríguez-Alcázar et al., 2019).
Galectin-3 is a chemoattractant for monocytes (Sano et al., 2000) and endothelial cells
(Nangia-Makker et al., 2000) while galectin-9 is a chemoattractant for eosinophils
(Matsumoto et al., 1998). Immune cell types often work together in the immune response
(Karlsson et al., 2009., Robinson et al., 2019) thus for neutrophil-like cells to secrete
these galectins which bring in other cell types to aid in the pathogen clearance response is
expected based on previous literature and is observed in this study as well.
The findings with galectin-1 are both consistent and inconsistent with findings by other
researchers as galectin-1 has many reported roles and expression patterns, some of which
appear contradictory. I showed here that galectin-1 secretion is significantly increased
only when treated with DON. Treatment with DON in this study was the only drug
treatment that led to a substantial increase in the proportion of dead cells. Galectin-1 is
reported to induce phosphatidylserine exposure in neutrophils and HL-60 cells (DiasBaruffi et al., 2003). Phosphatidylserine exposure signals apoptosis and cell death so it is
only logical that the treatment that caused much galectin-1 secretion also had
significantly more dead cells by inducing phosphatidylserine exposure through an
autocrine signaling method. Galectin-1 has also been shown to induce ROS production in
neutrophils (Elola et al., 2005; Ashraf et al., 2018) and is involved in neutrophil
chemotaxis (Auvynet et al., 2013). High LGALS1 expression is correlated with lower
survival in clear cell renal carcinoma patients and patients with low LGALS1 expression
showed higher survival rates in Kaplan-Meier curves (Li et al., 2019). Similar results
were also seen in vivo. Mice injected peritoneally with OCI-AML3 cells which are
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another immortalized M3 leukemia cell line were followed for 14 weeks after being
transfected with LGALS1 shRNA. Those mice with the LGALS1 knockdown survived
significantly longer, with 40% of mice surviving to 100 days whereas mice injected with
OCI-AML3 cells expressing wild-type LGALS1 all died by day 50 (Ruvolo et al., 2020).
This is consistent with my results which showed high LGALS1 expression in rapidly
dividing HL-60 cells, and low expression in differentiated cells that show growth arrest.
OCI-AML3 cells with suppressed LGALS1 showed significantly increased expression of
apoptotic markers p21, Mdm2, and APAF1 (Ruvolo et l., 2020). High galectin-1 is
associated with high programmed death ligand 1 levels in AML cells and in head and
neck cancers (Li et al., 2019; Nambiar et al., 2019). Knockdowns that reduce LGALS1
expression lower the programmed death ligand 1 levels in AML cells and made these
cells less susceptible to anti-programmed death ligand 1 treatment (Li et al., 2019).
Indeed, LGALS1 should be considered a biomarker of the cancer cell and not the
differentiated cell as might be concluded from the result shown here with DON, and in
previous literature (Vinnai et al., 2017).

4.1.4 Galectin gene expression correlates with O-GlcNAcylation and
differentiation.
The correlation analyses conducted in this study indicate strong correlations, in some
cases positive and in others negative, between O-GlcNAcylation, neutrophilic
differentiation, and expression of galectins. The correlations between neutrophilic marker
NCF1 and O-GlcNAc with galectins show galectins are involved in differentiation and
that their expression may be regulated by O-GlcNAc-mediated mechanisms. Specifically,
LGALS1, LGALS3, and LGALS8 are all negatively correlated with O-GlcNAcylation
(Figure 17 A-C), the only galectins to show any correlation with O-GlcNAc homeostasis.
This represents a novel finding as the regulation of galectins in response to manipulation
of global O-GlcNAcylation is not well documented.
The same galectins that were correlated with O-GlcNAcylation are also correlated with
the expression of a neutrophilic specific biomarker NCF1, albeit the correlation here is
strongly positive for all three galectins, LGALS1, LGALS3, and LGALS8 (Figure 18A-C).
All galectins except for LGALS9 were negatively correlated with the expression of
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oncogenic marker MYC. While the correlation is negative and mildly significant between
LGALS10 and LGALS12 with MYC, the correlation of MYC with the O-GlcNAc sensitive
galectins LGALS1, LGALS3, and LGALS8 is a stronger negative correlation with a higher
degree of significance (Figure 19).
Unsurprisingly, NCF1 is strongly negatively correlated with O-GlcNAcylation, while
MYC is strongly positively correlated with O-GlcNAcylation (Figure 21). These findings
indicate a strong association between O-GlcNAcylation of cytosolic proteins with the
differentiation state of the cells and many galectins correlate with O-GlcNAcylation and
with markers of differentiation. Although growth arrest is not uniformly affected by
differentiation and by O-GlcNAc stress, galectin expression and secretion follow the
same trends indicating that galectins are biomarkers for both processes, but galectins may
also be necessary for neutrophilic differentiation given their upregulation in HL-60 cells.
There is an association between O-GlcNAcylation and the secretion of galectins by HL60 cells. Only two galectins are verified to be O-GlcNAcylated in the literature, galectin1, and galectin-3 (Hart et al., 2011; Mathew et al., 2021). My study clearly demonstrates
an association between the reduction of global O-GlcNAcylation and increased secretion
of all galectins tested (-1, -3, -9, and -10) suggesting that galectin secretion is regulated
by O-GlcNAcylation and that other galectins are subject to O-GlcNAcylation.

4.2 Conclusions and applications
In conclusion, while differentiation appears to be induced both by ATRA and by DON,
not all galectin profiles are similarly inducible by the various drugs capable of
stimulating differentiation. Specifically, galectin-1 and its gene LGALS1 displayed
opposite patterns with ATRA and DON where both the gene and protein where
significantly lower in HL-60 cells induced by ATRA yet were significantly higher in HL60 cells induced by DON. This differs from previous reports (Zhao et al., 2011; Vinnai et
al., 2017) that galectin-1 ought to increase with neutrophilic differentiation by DMSO yet
is consistent with the findings of Chiarotti et al. (1994), and with Vakrushev et al. (2018)
who reported that LGALS1 expression decreased upon ATRA-treatment specifically in
HL-60 cells.
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While the expression profiles of some galectins appear similar throughout my present
studies using ATRA as a differentiation stimulus and is consistent with previous literature
(Abedin et al., 2003., Vinnai et al., 2017) which used DMSO to induce differentiation,
there are some inconsistencies such as that of LGALS1 and LGALS12. It must be
considered that DMSO and ATRA induce differentiation by different means and as such
the biochemical and physiological changes of the cell induced by each drug may not be in
perfect alignment. Manda-Handzlik (2018) examined differentiation in HL-60 cells
induced by three different drugs, ATRA, DMSO, and dimethyl formamide. While some
markers of differentiation are highly upregulated regardless of stimuli, other markers are
more strongly induced with a specific stimulus but show weaker induction with other
stimuli (Sham et al., 1995; Manda-Handzlik et al., 2018). Manda-Handzlik et al. (2018)
also showed that some characteristics of neutrophil like cells are missing altogether from
differentiated in vitro HL-60 cells. For example, calcium-ionophore induced calcium
influx varies depending on the differentiation-inducing agent used. Specifically, these
researchers reported ATRA-differentiated cells were resistant to calcium ionophoreinduced calcium influx whereas DMSO and dimethyl formamide differentiated cells
showed no statistical difference in this measure from healthy peripheral blood
neutrophils.
Little information exists on the expression patterns of galectins in the context of
neutrophilic differentiation of HL-60 cells (Abedin et al., 2003; Vinnai et al., 2017), and
there appears to be no published study on how different inducers differentially regulate
the expression patterns of these galectins. My findings are consistent with previous work
by Sham et al. (1995) and Manda-Handzlik et al. (2018) in that the fold change of
markers may not be consistent across differentiation stimuli and in that the direction of
change, upregulation, or downregulation, are not consistent across different stimuli.
Indeed, much work remains to be done in the future to explain the roles of galectins in
neutrophilic differentiation and in relation to O-GlcNAc homeostasis. What transcription
factor(s) are activated or suppressed in any given drug treatment? What roles do galectins
play in the differentiation of the cell? Or in the function of the differentiated cell? Future
work could expand on the approach of Manda-Handzlik et al. (2018) using different
induction stimuli and incorporate the work from our laboratory with regards to
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glycobiology to elucidate how galectins and O-GlcNAc participate in the neutrophilic
differentiation and in the functions of mature neutrophils.
The role of galectin-12 in neutrophilic differentiation remains elusive. The seemingly
contradictory results here with LGALS12 are also seen with the galectin-1 gene LGALS1.
However, the contradictory expression profile of LGALS1 in neutrophil-like
differentiated cells can be supported by previous reports where the downregulation of
LGALS1 by ATRA reported elsewhere (Vakrushev et al., 2018) differs from reports of
the upregulation of LGALS1 by DMSO (Vinnai et al., 2017). What roles do these
galectins play in differentiation? It is possible that the expression of these genes and their
proteins may not be related to the neutrophilic differentiation of HL-60 cells or that
different pathways that regulate these genes could be acted upon by these different drugs.

4.3 Study limitations and future directions
While it is certainly nice that we can show neutrophilic differentiation of HL-60 cells by
targeting the HBP and bypass the ATRA-RAR interaction, we must remember that this
O-GlcNAc mediated differentiation occurs in M2 leukemia cells which are notably
susceptible to ATRA-induced differentiation. It remains to be seen if the O-GlcNAcmediated neutrophilic differentiation can be induced in ATRA-resistant AML. This could
be accomplished in a number of ways. There is the possibility to knock out the RAR to
see if the signaling through this receptor is important even in the absence of ATRA when
using inhibitors of OGT or GFAT. RNA interference techniques could also be used
although these would be more transient. The obvious next step I would take is to acquire
known ATRA-resistant cell lines like the NB4/RA cell line (Takeshita et al., 2000) and
look to see if this O-GlcNAc-mediated differentiation bypassing the ATRA-RAR
interaction is possible. This would provide much insight into the clinical treatment of
ATRA-resistant AML.
To change O-GlcNAc levels in HL-60, we used biochemical inhibitors which may also
have non-target effects on cells. This aspect was not addressed in this study and
potentially could be responsible for variations in the effects of OGT and GFAT inhibitors
we used on galectin expression and neutrophilic differentiation, although both treatments
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induced an inhibition of O-GlcNAc. Optimization of the treatment conditions as well as
genetic manipulations with relevant genes might be a good strategy for future studies.
The inability to confirm O-GlcNAcylation of specific galectin proteins represents a
limitation of this work. We were also unable to confirm the O-GlcNAcylation of specific
galectins. Due to time constraints, we were unable to work with the Biological Mass
Spectrometry Lab (Biochemistry Department, UWO) to assess the O-GlcNAcylation of
peptides. While we attempted to use western blot to look for overlaps in bands
corresponding to galectins with the O-GlcNAc specific antibody RL2, the signal elicited
by this antibody is very weak at lower molecular weights, and there is much signal from
higher molecular weight proteins. As galectins are low molecular weight proteins, future
studies most certainly should aim to do what I initially intended to do in my proposal by
enriching cell lysates for galectins as per the protocol described in Timoshenko et al.
(2014) and using UPLC-MS/MS to identify O-GlcNAcylated peptides. A secondary goal
with be to assess whether galectins must be de-glycosylated prior to secretion. I showed
that four galectins (-1, -3, -9, and -10) are secreted at significantly higher concentrations
when cells were treated with a GFAT inhibitor DON relative to untreated cells. A study
designed to assess galectin O-GlcNAcylation and subsequent de-glycosylation should
look at both intracellular and extracellular galectins to examine what if any differences in
the amount of, or site of this modification exist and how this relates to secretion.
Future work will also investigate the apparent differences in induction and suppression of
LGALS1 and LGALS12. My results differ from previous literature by Vinnai et al. (2017)
who reported that upon DMSO-induced differentiation, LGALS1 and LGALS12 exhibit
increased expression and decreased expression, respectively. Since my project looked at
all galectins expressed in HL-60 cells and focused on O-GlcNAc mediated
differentiation, I did not specifically look at the genetic regulation of any one galectin.
Future studies may focus on a single galectin expressed in HL-60 and attempt to better
explain the genetic regulation while accounting for differences in expression when
treated with different granulocyte-inducing chemicals.
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Appendix A: Supplementary Material
Table S1: Initial and final densities, and cell viability of HL-60 cell cultures grown in
IMDM + 10% FBS treated with differentiation agents and O-GlcNAc cycle enzyme
inhibitors for 72 hours.

Initial Cell Concentration

CTRL

ATRA

AC 25 M

AC 50 M

DON

TG
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1.0

1.5

1.0

1.5

4.0

1.0

4.5

9.5

7.9

8.6

4.6

4.4

8.2

5.3

96.7

93.4

94.6

69.7

68.7
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Cell Viability (%)
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Figure S1: HL-60 cells were treated with two known inducers of neutrophilic
differentiation, 1 M ATRA and 1.3% DMSO for 72 hours and were tested for LGALS12
transcript abundance relative to untreated cells, n=1.

Figure S2: Immunodot blots for serum galectins in IMDM media supplemented with
10% FBS (top) or 1X ITS (bottom). Unconditioned media was gravity filtered through an
Immunodot blot micro-apparatus and the presence of galectins was confirmed using antigalectins antibodies.
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